[{"ID": "CANIMM/2224", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": "Adenocarcinoma", "Patient_Sample": "3", "Male/Female": "2024-01-02 00:00:00", "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2225", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Carcinoma", "Patient_Sample": "2", "Male/Female": "2024-01-01 00:00:00", "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2226", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Pleural Mesothelioma", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2227", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer -Clear Cell Ovarian Cancer", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2230", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2231", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "16960692", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": "CTX 50 mg orally, twice a day 1 week on and 1 week oV for 1 month or more", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "T lymphocyte, CD3+ T cell, CD8+ T cell, and CD3,CD56 and NK cells", "Controlled_Terms_Unaffected": "NK cells; CD8+ T cells; T cells; Lymphocytes; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2256", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "28855352", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Metastatic Colorectal Cancer", "Patient_Sample": "(n = 27)", "Male/Female": "2024-09-18 00:00:00", "Median_age/Range": "65.2", "Dose": "2-week-long courses of low-dose (50 mg twice a day)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+ T-cells IFNγ intracellular perforin and granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Perforin / PRF1; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ T cells expressing CD25hi/Foxp3-T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD4+ T cells; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2270", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21148486", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Advanced Cancer Including Melanoma", "Patient_Sample": "21", "Male/Female": "2024-12-09 00:00:00", "Median_age/Range": "51 (27–74)", "Dose": "50 mg/d", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD4 T cells as the major source of IL-17A", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; T cells; IL-17", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2179", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29721378", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "N=6", "Male/Female": "3M/3F", "Median_age/Range": "42 (range 23–58)", "Dose": "oral vemurafenib (960 mg twice daily) for\n 2 weeks", "Technique": "IHC, Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells, CD4+ FoxP3+ regulatory T cells\n and CD11b+ myeloid cells", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD4+ T cells; CD8+ T cells; T cells; CD11b / ITGAM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2181", "Drug": "BRAF-targeted therapies-BRAFi (vemurafenib)/ (dabrafenib + trametinib)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "24251082", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "serial biopsies collected before treatment and 10–14 d after the initiation of BRAF-targeted therapy from 8 metastatic melanoma patients harboring BRAF mutations", "Male/Female": null, "Median_age/Range": "25 - 72 y", "Dose": null, "Technique": "CDR3 sequencing", "Controlled_Technique": "Gene expression/sequencing analysis; CDR3 sequencing", "Immune_System-Function_enhanced/numbers_increased": "TIL clonality,influx of T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-infiltrating lymphocytes (TILs); T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2194", "Drug": "BRAF inhibitor (vemurafenib)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "23307859", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "patients 1-5", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "immunohistochemistry and immunofluorescence, Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltrate   MART, TYRP-1. TYRP-2, and GP100- Melanoma antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; MART antigen; gp100 antigen; TYRP-1; TYRP-2", "Immune_System-Function_inhibited/numbers_decreased": "immunosuppressive cytokines IL-6 and IL-8 markers of T cell cytotoxicity (perforin, granzyme B)", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; IL-6; IL-8 / CXCL8; Perforin / PRF1; Granzyme B / GZMB; Cytotoxicity / cytolysis", "Immune_System_function_unaffected": "CD4+ T cell infiltrate TGF-beta and IL-10 HLA expression", "Controlled_Terms_Unaffected": "CD4+ T cells; T cells; IL-10; TGF-β", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "T cell exhaustion markers TIM3 and PD1, immunosuppressive ligand PDL1", "Controlled_Terms_Negative_Regulation": "T cells; PD-1 / PDCD1; PD-L1 / CD274; TIM-3"}, {"ID": "CANIMM/2195", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "paired BRAFV600E positive tumor biopsies from patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "qPCR analysis,histology", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": "CD68, M1 marker CD86 and the M2 marker CD163-indicating an accumulation of M1 and M2 polarized macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; CD86; CD68; CD163", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNFα expression  MITF expression", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; MITF"}, {"ID": "CANIMM/2209", "Drug": "Dabrafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Pubchem_ID": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "Melanoma biopsies from patients treated at the Melanoma Institute Australia Sydney and the Netherlands Cancer Institute", "Male/Female": null, "Median_age/Range": null, "Dose": "150 mg orally, twice daily", "Technique": "Flow cytometry, immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltrates", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/17", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": null, "PMID": "19797418", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Patient_Sample": "28 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "gemcitabine 1000 mg/m(2) for 3 weeks, followed by 1 week of rest", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD14(+) monocytes and CD11c(+) (myeloid) DC, CD123(+) (plasmacytoid) DC", "Controlled_Terms_Function_enhanced_Number_increased": "Monocytes; Dendritic cells; CD14; CD11c / ITGAX", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2210", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "Melanoma biopsies from patients treated at the Melanoma Institute Australia Sydney and the Netherlands Cancer Institute", "Male/Female": null, "Median_age/Range": null, "Dose": "960 mg orally twice daily", "Technique": "Flow cytometry, immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltrates", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2279", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "24504444", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "(n = 277)", "Male/Female": "164/113", "Median_age/Range": "56 (21–84)", "Dose": "Flow cytometry", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "NK cells, CCR7(+)CD45RA(+) (naïve)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; CCR7; CD45RA", "Immune_System-Function_inhibited/numbers_decreased": "a significant decrease in peripheral lymphocytes within the first 12 weeks of treatment, neutrophil counts, CD4+ T cell compartment, CD8+ T cells , , CD4+ T cells with a central memory phenotype, T cells (Th1), loss of peripheral lymphocytes interferon-γ and interleukin-9 by CD4(+) T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4+ T cells; CD8+ T cells; T cells; Neutrophils; Lymphocytes; IFN-γ; IL-9; Th1 cells; Central memory T cells", "Immune_System_function_unaffected": "B cells IL-2, IL-4, IL-10 and IL-17A", "Controlled_Terms_Unaffected": "B cells; IL-2; IL-4; IL-10; IL-17", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2280", "Drug": "Dabrafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Pubchem_ID": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Single Drug", "PMID": "24504444", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "(n = 65)", "Male/Female": "41/24", "Median_age/Range": "51 (20–79)", "Dose": "Flow cytometry", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "neutrophil counts", "Controlled_Terms_Function_inhibited_Number_decreased": "Neutrophils", "Immune_System_function_unaffected": "peripheral lymphocytes", "Controlled_Terms_Unaffected": "Lymphocytes", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2183", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "16297208", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "Patient_Sample": "n=11", "Male/Female": "2024-07-04 00:00:00", "Median_age/Range": "44-81", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2185", "Drug": "Benzamide-derived MS-275, Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia  - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "80 CLL patients", "Male/Female": null, "Median_age/Range": null, "Dose": "ibrutinib 420 mg orally once daily until disease progression or the occurrence of intolerable side effects", "Technique": "Luminex 200 instrument (Luminex) for determination of individual cytokine concentrations,immunohistochemistry, Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "Eotaxin", "Controlled_Terms_Function_enhanced_Number_increased": "Eotaxin / CCL11", "Immune_System-Function_inhibited/numbers_decreased": "circulating T cells, CD4+ T cells that expressed HLA-DR or CD39, CD8+ cells expressing HLA-DR , PD-1 expression on T cells, CD4+ Th17 T cells (CXCR3neg, CCR6+),Macrophage-CLL cell interactions CCL22, IL-8, CXCL10, CCL2, CCL3, CCL4, and CCL7, IL-10, IL-1ra, TNFα, IFNα,IFNγ, IL-4", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4+ T cells; CD8+ T cells; T cells; Macrophages; IFN-γ; IFN-α; IL-4; IL-8 / CXCL8; IL-10; TNF-α / TNF; CCL2 / MCP-1; CCL3 / MIP-1α; CCL4 / MIP-1β; CCL7; CXCL10 / IP-10; PD-1 / PDCD1; HLA-DR; IL-1Ra; Th17 cells; CCL22; CD39", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2273", "Drug": "SAHA/Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "23", "Male/Female": "14M/9F", "Median_age/Range": "Median 69 (61–85)", "Dose": "Lenalidomide:2.5-5 mg/day daily for first 4 weeks; week 5 to week 12: 30 mg (thrice in a week); then lenalidomide escalted stepwise upto 15mg/day upto 16 weeks", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Ki67+CD8+, HLA-DR+ cells; effector memory CD8+ cells;", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-DR; Ki-67; Effector memory T cells", "Immune_System-Function_inhibited/numbers_decreased": "effector cells (CD4+ and CD8+)", "Controlled_Terms_Function_inhibited_Number_decreased": "Effector CD4-positive T cells; Effector CD8-positive T cells", "Immune_System_function_unaffected": "CD4+ T cells, CD8+ T cells, NK cells and NKT cells; Ki67+CD4+", "Controlled_Terms_Unaffected": "Natural killer T cells (NKT cells); NK cells; CD4+ T cells; CD8+ T cells; T cells; Ki-67", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2274", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "23", "Male/Female": "14M/9F", "Median_age/Range": "Median 69 (61–85)", "Dose": "Lenalidomide:2.5-5 mg/day daily for first 4 weeks; week 5 to week 12: 30 mg (thrice in a week); then lenalidomide escalted stepwise upto 15mg/day upto 16 weeks", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD52− T cells, HLA-DR+ cells; effector memory CD4+ and CD8+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; HLA-DR; Effector memory T cells; CD52", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ T cells, CD8+ T cells, NK cells and NKT cells; naïve CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Natural killer T cells (NKT cells); NK cells; CD4+ T cells; CD8+ T cells; T cells", "Immune_System_function_unaffected": "Central memory T cells, PD-1+ cells CTLA-4", "Controlled_Terms_Unaffected": "T cells; PD-1 / PDCD1; CTLA-4; Central memory T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2182", "Drug": "Thalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug_ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "11418482", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "5 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "Thal 200 to 800 mg/day", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "The 3 patients responding to treatment showed an increase in the percentage of CD561 NK cells (fold increases of 5.6, 2.7, and 2.1) compared to patients who failed to respond (fold increases of 0.5 and 1.2 IL-2 and IFN-γ (in patient having good partial response)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; IFN-γ; IL-2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2192", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "21748755", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate - Recurrent Prostate Cancer", "Patient_Sample": "49 of the 51 available patient samples", "Male/Female": null, "Median_age/Range": null, "Dose": "5mg or 25mg of lenalidomide", "Technique": "High Throughput Immunoblot Analysis, multiplexed bead-based immunoassay for cytokine detection", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "IL-2, IL-4, IL-5, IL-10, IL-13, and G-CSF  immunoreactivity to prostate-associated antigens", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; IL-4; IL-5; IL-10; IL-13; G-CSF / CSF3; Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2205", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "16569772", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "MDS", "Patient_Sample": "5(el5q MDS)", "Male/Female": null, "Median_age/Range": null, "Dose": "10 mg/day", "Technique": "Flow cytometry,real-time RT-PCR (TaqMan) analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKT cells expansion IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "Natural killer T cells (NKT cells); IFN-γ; NKT cells; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2207", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30104242", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Relapsed Chronic Lymphocytic Leukemia (CLL)", "Patient_Sample": "Thirty-three patients with relapsed CLL", "Male/Female": null, "Median_age/Range": null, "Dose": "lenalidomide at 10 mg or 20 mg daily for 3 weeks followed by 3 weeks off for up to 8 cycles", "Technique": "gene expression profiling ( on circulating CD19+-selected cells from 11 patients ), Flow cytometry, Immunohistochemistry, Deep sequencing", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "IFNγ+ CD4+ and CD8+ T cells chemokines (CCL3, CCL4), cytokines or cytokine receptors (IL13RA1, TNF, TNFSF13B), signal transduction molecules (STK3, RCAN1, KSR2) and molecules involved in the regulation of apoptosis (DDIT4, PAPRP9, CFLAR), IFNγ signaling pathway  TBX21 encoding T-bet( in the LN biopsies of responders compared to non-responders)", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; CD8+ T cells; T cells; IFN-γ; TNF-α / TNF; CCL3 / MIP-1α; CCL4 / MIP-1β; Apoptosis; TNFSF13B / BAFF; IL13RA1", "Immune_System-Function_inhibited/numbers_decreased": "decreasing diversity of the T-cell repertoire and an expansion of select clonotypes in responders", "Controlled_Terms_Function_inhibited_Number_decreased": "decreasing diversity of the T-cell repertoire and an expansion of select clonotypes in responders", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2215", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27467960", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "58 patients with (n = 30) or without (n = 28) lenalidomide therapy and 12 patients refractory to lenalidomide", "Male/Female": null, "Median_age/Range": null, "Dose": "a consolidation therapy with two cycles of lenalidomide (25 mg on day 1–21, cycle duration 28 d). Half of the study population continued treatment with lenalidomide maintenance therapy for 2 y (10 mg daily for 3 mo, if tolerable dose escalation to 15 mg/d from the 4th mo), while the other patients received lenalidomide maintenance therapy until complete remission", "Technique": "IFNγ ELISpot-assays, IFNγ-, Granzyme B and Perforin-ELISAs, Flow cytometry", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "HM1.24aa22-30 specific T-cell responses IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "CD57 on CD8+ T-cells (n = 19)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD57", "Immune_System_function_unaffected": "CD28 (n = 37), CCR7 (n = 37), PD-1 (n = 39) CD38 (n = 19), CD154 (n = 19) and HLA-DR (n = 19)", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CD28; HLA-DR; CCR7; CD154 / CD40 ligand; CD38", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CD4+CD127dimCD25highFoxp3+regulatory T-cells of CD4+ T cells ((n = 18)", "Controlled_Terms_Negative_Regulation": "Regulatory T cells (Tregs); CD4+ T cells; T cells"}, {"ID": "CANIMM/2217", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29755666", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "17", "Male/Female": "8M/9F", "Median_age/Range": "51.7-66 (median 59.2)", "Dose": null, "Technique": "Flow cytometry , bioplex", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "naïve CD8+ T cells,stem\n cell memory CD8+ T cells, central memory CD4+ and CD8+ T cells, transitional memory T\n cells (both CD4+ and CD8+), effector memory T cells, NKT cells, CD4+ CD25high CD127low Foxp3high Tregs, CD28+ CD4+ cells, CD28+ CD8+ cells,CD137+ CD4+ cells, CD137+ CD28+ CD8+ cells, ICOS+ CD4+ cells, ICOS+ CD8+ cells, TIGIT on both CD4+ and CD8+ T-cell IL-8, IFN-γ, MIP-1β, TNF-α CD28, CD137/4-1BB and ICOS", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); Natural killer T cells (NKT cells); CD4+ T cells; CD8+ T cells; T cells; IFN-γ; IL-8 / CXCL8; TNF-α / TNF; CCL4 / MIP-1β; 4-1BB / CD137; CD28; Central memory T cells; Effector memory T cells; ICOS / CD278", "Immune_System-Function_inhibited/numbers_decreased": "effector memory CD4+ T cells, terminal effector T cells, monocytic MDSCs (CD33+ CD11b+\n CD14+ HLA-DRlow), CD45RA+ Tregs, PD-1,\n TIM-3 and LAG-3 on T cells,", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs); Monocytic myeloid-derived suppressor cells (M-MDSCs); CD4+ T cells; T cells; PD-1 / PDCD1; TIM-3; LAG-3; CD14; Effector memory T cells; CD45RA; CD11b / ITGAM; CD33", "Immune_System_function_unaffected": "naïve CD4+ T cells, stem cell memory\n CD4+ T cells, NK cell", "Controlled_Terms_Unaffected": "NK cells; CD4+ T cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2223", "Drug": "Thalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug_ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "16569772", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Myeloma", "Patient_Sample": "2 (myeloma )", "Male/Female": null, "Median_age/Range": null, "Dose": "50 mg/d to 100 mg/d", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKT cells expansion", "Controlled_Terms_Function_enhanced_Number_increased": "Natural killer T cells (NKT cells); NKT cells; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2235", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "21149673", "Cancer_Type": "Myelodysplastic Syndrome", "Cancer_Type_Description": "Recurrent Or Refractory Solid Tumors Or Myelodysplastic Syndrome (MDS)", "Patient_Sample": "N=49", "Male/Female": "26M/23F", "Median_age/Range": "median 16 (1-21)", "Dose": "5mg/day", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK (CD3-/\n 16+/56+) cells, granzyme B, LAMP-1, IL-2, IL-15, GM-CSF KIR3DL1 (CD158b+) receptor, KIR2DS4 receptor, Nkp46, CD107a", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; IL-15; GM-CSF / CSF2; CD107a / LAMP1; Granzyme B / GZMB; KIR3DL1; KIR2DS4; NKp46 / NCR1", "Immune_System-Function_inhibited/numbers_decreased": "Treg cells (CD4+/CD25+)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD25 / IL2RA", "Immune_System_function_unaffected": "IL-8 CD94/NKG2a", "Controlled_Terms_Unaffected": "IL-8 / CXCL8; NKG2A", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2240", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "24244687", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer - Kras-Mutant Metastatic Colorectal Cancer", "Patient_Sample": "N=21", "Male/Female": "12 M, 9F", "Median_age/Range": null, "Dose": "Lenalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells, T regulatory cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": "B cells , T helper cells, Absolute T cells , Absolute lymphocytes", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; B cells; Lymphocytes", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2246", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "25313353", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "Patient_Sample": "22", "Male/Female": null, "Median_age/Range": null, "Dose": "70 mg twice daily and dose reductions were made in case of toxicity", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "lymphocytosis-cytotoxic T-cell and NK-cell", "Controlled_Terms_Function_enhanced_Number_increased": "Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2277", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "24032527", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "n=11", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "NKT cell frequency  CD25", "Controlled_Terms_Unaffected": "Natural killer T cells (NKT cells); CD25 / IL2RA", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2278", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "24032527", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Relapsed/Refractory Myeloma", "Patient_Sample": "n=23", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "NKT cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Natural killer T cells (NKT cells)", "Immune_System_function_unaffected": "CD4+, CD4− and CD8+", "Controlled_Terms_Unaffected": "CD4-positive T cells; CD4-negative T cells; CD8-positive T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2281", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "25748683", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "10", "Male/Female": null, "Median_age/Range": "49.1–64.4 Median =60.3", "Dose": "5 to 15 mg/day.", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IP-10, IL-8, MIP-1b", "Controlled_Terms_Function_enhanced_Number_increased": "IL-8 / CXCL8; CXCL10 / IP-10", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2282", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29191843", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "n=20", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": "programmed death-1 (PD1, CD279)", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2283", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "31950647", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Relapsed Or Refractory Multiple Myeloma (RRMM)", "Patient_Sample": "59", "Male/Female": "30M/29F", "Median_age/Range": "45-89 median=73", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2180", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "Patient_Sample": "n=17", "Male/Female": "15M/2F", "Median_age/Range": null, "Dose": null, "Technique": "RT-PCR and IHC/ICC,", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "TAP-2", "Controlled_Terms_Function_enhanced_Number_increased": "TAP2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2184", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "Patient_Sample": "(n=24)- clinical responders (n=7) but not in non-responders (n=17)", "Male/Female": null, "Median_age/Range": null, "Dose": "(cetuximab IV 400mg/m2 day 1 then 250 mg/m2 alone days 8, 15, and 22)", "Technique": "IHC and digital image analysis", "Controlled_Technique": "Immunohistochemistry (IHC); Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA-B expression, HLA-A -in clinical responders (n=7) STAT-1-in clinical responders (n=7)", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-A; HLA-B; STAT1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2196", "Drug": "Pembrolizumab (formerly MK-3475 and lambrolizumab)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Pembrolizumab binds with high affinity to the cell surface receptor programmed cell death protein 1 (PD-1) and antagonizes its interaction with its known ligands PD-L1 and PD-L2.", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "348000000", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25428505", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Advanced Melanoma", "Patient_Sample": "46 patients", "Male/Female": "36/10", "Median_age/Range": "responders-65 (45–90) , progression- 64 (36–86)", "Dose": "pembrolizumab intravenously in one of three dosing regimens: 2 mg/kg every 3 weeks (2Q3W), 10 mg/kg every 3 weeks (10Q3W), or 10 mg/kg every 2 weeks (10Q2W)", "Technique": "immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing", "Controlled_Technique": "Immunohistochemistry (IHC); Immunofluorescence assay; Cytokine/multiplex immunoassay; Gene expression/sequencing analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "intratumoral CD8(+) T cells in treatment responders", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2199", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Patient_Sample": "n=23 patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy adaptor protein, SQSTM1/p62 in non responders- associated with a worse prognosis", "Controlled_Terms_Negative_Regulation": "SQSTM1 / p62"}, {"ID": "CANIMM/2206", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26579227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Patient_Sample": "Total=29,Responders =10, Non-responders=9", "Male/Female": "2024-09-20 00:00:00", "Median_age/Range": "Responders =60, Non-responders=59", "Dose": null, "Technique": "Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monoctyic MDSC and granulocytic MDSC in the peripheral circulation-in responders,CD163+ cells and IL-10 transcripts in circulating CD11b+CD14+HLA-DRhi monocytes-in responders IL-10", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs); Granulocytic myeloid-derived suppressor cells (G-MDSCs); Monocytes; IL-10; CD14; CD163; CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "monocytic MDSC in CD11b+ cells-In non responders", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells (MDSCs); Monocytic myeloid-derived suppressor cells (M-MDSCs); CD11b / ITGAM"}, {"ID": "CANIMM/2234", "Drug": "Bevacizumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00112", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.", "KEGG_Drug_ID": "D06409", "Pubchem_ID": "46504473", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19414323", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Advanced Colon Cancer With Multiple Metastases", "Patient_Sample": "4", "Male/Female": "2024-02-02 00:00:00", "Median_age/Range": null, "Dose": "(5 mg/kg) every 2 weeks by intravenous injection", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2247", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25832655", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "Patient_Sample": "(n=18)", "Male/Female": "2024-06-12 00:00:00", "Median_age/Range": "59.7", "Dose": "Cetuximab 250 mg/m2 weekly (after an initial dose of 400 mg/m2)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "circulating and intratumoral NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CD4+CD25hiFoxp3+ intratumoral Treg TGF-β-on T reg CD39 on T reg CTLA-4 on T reg,CD4+Foxp3+ Treg expressing TIM-3", "Controlled_Terms_Negative_Regulation": "Regulatory T cells (Tregs); TGF-β; CTLA-4; TIM-3; CD39"}, {"ID": "CANIMM/2252", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27496866", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "Patient_Sample": "(n=5 responders, n=12 non responders)", "Male/Female": null, "Median_age/Range": null, "Dose": "(cetuximab IV 400 mg/m2 day 1 then 250 mg/m2 alone days 8, 15, and 22 (UPCI 08-013)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell expression of CD137  CD137", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; 4-1BB / CD137", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2255", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28408386", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNSCC)", "Patient_Sample": "(n = 18)", "Male/Female": null, "Median_age/Range": null, "Dose": "Cetuximab 250 mg/m^2 was weekly injected and 400 mg/m^2 after an initial dose", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "granzyme B- and perforin-expressing CD8+ TILs", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-infiltrating lymphocytes (TILs); Perforin / PRF1; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CTLA-4+, PD-1+, and TIM-3+CD8+ TILs", "Controlled_Terms_Negative_Regulation": "Tumor-infiltrating lymphocytes (TILs); PD-1 / PDCD1; CTLA-4; TIM-3"}, {"ID": "CANIMM/2257", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29179214", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "(n =63)", "Male/Female": "39/24", "Median_age/Range": "34–74 years", "Dose": "250 mg/m^2 body weight every week after a loading dose of 400 mg/m^2", "Technique": "Flow cytometry,enzyme immunoassay\n system", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells, CD8+ T cells and NK cells IFN-γ CD137 expression on NK cells and CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; CD8+ T cells; T cells; IFN-γ; 4-1BB / CD137", "Immune_System-Function_inhibited/numbers_decreased": "Treg cells IL-6 and IL-10 gradually", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); IL-6; IL-10", "Immune_System_function_unaffected": "CD4+ T cells, NKT-like cells, iNKT cells and DCs", "Controlled_Terms_Unaffected": "Natural killer T cells (NKT cells); CD4+ T cells; T cells; Dendritic cells; iNKT cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/38", "Drug": "Bevacizumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00112", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.", "KEGG_Drug_ID": "D06409", "Pubchem_ID": "46504473", "STR_LINK_(SMILES)": null, "Single/Combination": null, "PMID": "30889935", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Patient_Sample": "N=10", "Male/Female": null, "Median_age/Range": "54 years (42y–67y)", "Dose": "bevacizumab 5 mg/kg every 21 days (6 cycles of treatment)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4 T cells, CD4/CD8 ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "activated Tregs (CD25highCD45RA-FOXP3-: aTregs), resting Treg (CD25+CD45RA+FOXP3+: rTregs)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD25 / IL2RA; CD45RA", "Immune_System_function_unaffected": "CD8 T cells", "Controlled_Terms_Unaffected": "CD8+ T cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2238", "Drug": "Everolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies", "KEGG_Drug_ID": "D02714", "Pubchem_ID": "46505248", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "23582881", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Patient_Sample": "37", "Male/Female": null, "Median_age/Range": "62 (45–76)", "Dose": "Everolimus 10 mg daily was taken continuously until disease progression, unacceptable toxicity, symptomatic deterioration, delay of trial treatment >2 wk, patient refusal, or initiation of radiotherapy. In case of relevant toxicities, everolimus was reduced to 5 mg/d and to 5 mg every second day in case of reoccurrence of such toxicity", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "carboxypeptidase M (CPM) and apolipoprotein B (APOB)", "Controlled_Terms_Function_enhanced_Number_increased": "carboxypeptidase M (CPM) and apolipoprotein B (APOB)", "Immune_System-Function_inhibited/numbers_decreased": "CD3, CD4, and CD8 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8+ T cells; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "regulatory T cells (Tregs)", "Controlled_Terms_Negative_Regulation": "Regulatory T cells (Tregs); T cells"}, {"ID": "CANIMM/92", "Drug": "Platinum-based", "Drug_category": "Platinum compounds", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": null, "PMID": "29642771", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Adenocarcinoma", "Patient_Sample": "9 patients", "Male/Female": "2024-07-02 00:00:00", "Median_age/Range": "56.3 (35/74) years", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ PD-1+ T cells IL-12", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; T cells; IL-12; PD-1 / PDCD1", "Immune_System-Function_inhibited/numbers_decreased": "MIP-1β", "Controlled_Terms_Function_inhibited_Number_decreased": "CCL4 / MIP-1β", "Immune_System_function_unaffected": "IL-2", "Controlled_Terms_Unaffected": "IL-2", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "intermediate and classical HLA-DR+ IL-1beta and IL-5", "Controlled_Terms_Negative_Regulation": "IL-5; HLA-DR"}, {"ID": "CANIMM/2190", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28337274", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Myelodysplastic Syndrome (MDS)", "Patient_Sample": "17", "Male/Female": "2024-09-08 00:00:00", "Median_age/Range": null, "Dose": "(15 mg/M2, I.V.) over a period of 1 h once per day for 5 consecutive days. This course of treatment was repeated every 4 weeks", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD3 and CD8T lymphocyte counts, Th1 polarization in the CD4+ subset and Tc1 polarization in the CD8+ subset MHC Class I and Class II molecules, and ICAM-1 cancer-testis antigens (CTAs)-MAGE-A1, MAGE-A3, and SP17", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Lymphocytes; MHC class I; ICAM-1 / CD54; Th1 cells; MAGE-A1; MAGE-A3; SP17; MHC class I; MHC class II; Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2191", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "27687804", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Adenocarcinoma", "Patient_Sample": "10 patients", "Male/Female": "2024-04-06 00:00:00", "Median_age/Range": "70.3 ± 6 years and 71.3 ± 6.1 years,", "Dose": "(1000 mg/m2) once weekly for 3 weeks (day 1, 8, 15) followed by a resting phase for 2 weeks after the third treatment", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "effector T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "granulocytic MDSCs, Tregs TGFβ-1", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs); Granulocytic myeloid-derived suppressor cells (G-MDSCs); TGF-β", "Immune_System_function_unaffected": "IL-6, IL-8, IL-10 and TNFα", "Controlled_Terms_Unaffected": "IL-6; IL-8 / CXCL8; IL-10; TNF-α / TNF", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2193", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28337274", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia  - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "peripheral blood mononuclear cells isolated from CLL patient (n=8)", "Male/Female": null, "Median_age/Range": null, "Dose": "low-dose lenalidomide (2.5 mg)", "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "5/8 patients showed an increase in IL21R protein", "Controlled_Terms_Function_enhanced_Number_increased": "IL-21", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2198", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02371", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26449615", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Patient_Sample": "19 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "(800 mg/m2 )", "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "MICA expression in tumors was found in 18 of 19 (95 %) samples of the NAC group and CD16", "Controlled_Terms_Function_enhanced_Number_increased": "CD16 / FcγRIIIa; MICA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2212", "Drug": "Azacytidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug_ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "Patient_Sample": "12", "Male/Female": null, "Median_age/Range": "aged 65 ± 12.9 years", "Dose": null, "Technique": "sandwich ELISA, Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL expression in blasts", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2DL expression in blasts", "Immune_System-Function_inhibited/numbers_decreased": "sNKG2DL levels", "Controlled_Terms_Function_inhibited_Number_decreased": "Soluble natural killer group 2D ligands (sNKG2DLs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2222", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "15782312", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreas Cancer", "Patient_Sample": "Ten patients", "Male/Female": "2024-05-05 00:00:00", "Median_age/Range": null, "Dose": "1,000 mg/ m2 over 30 min at days 0, 7, 14, and 21", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "BDCA-1+, CD1b myeloid dendritic cell", "Controlled_Terms_Function_inhibited_Number_decreased": "Dendritic cells", "Immune_System_function_unaffected": "T and B-cells ,CD86 and CD80 APCs or CD4+, CD25+ T-cells", "Controlled_Terms_Unaffected": "CD80; CD86; CD25 / IL2RA; Antigen presentation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2236", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00585", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Patient_Sample": "24 patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Caspase-1 activation in MDSC", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells (MDSCs); Caspase-1"}, {"ID": "CANIMM/2237", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug_ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "23242597", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Myelodysplastic Syndrome (MDS)", "Patient_Sample": "68", "Male/Female": null, "Median_age/Range": "67 years (range, 35–86 years)", "Dose": "75 mg/m2/day", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Th1 and Th2 cells", "Controlled_Terms_Negative_Regulation": "Th1 cells; Th2 cells"}, {"ID": "CANIMM/2263", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "31217433", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "26 patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "caspase-1 activity in HLA-DR- CD33+ CD15+ MDSC", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells (MDSCs); HLA-DR; Caspase-1; CD33; CD15"}, {"ID": "CANIMM/2267", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Patient_Sample": "5 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "1000 mg/m2", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2271", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00585", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Patient_Sample": "12 patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β secretion from MDSCs", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells (MDSCs); IL-1 family"}, {"ID": "CANIMM/138", "Drug": "BRAF inhibitor (vemurafenib)+\n interleukin-2 (aldesleukin)", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "29721378", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "N=6", "Male/Female": "3M/3F", "Median_age/Range": "42 (range 23–58)", "Dose": "oral vemurafenib (960 mg twice daily) for\n 2 weeks, and then received HD-IL-2 at 600,000 IU/kg/dose\n intravenously every eight hours to tolerance (maximum\n 14 doses) over five days on days 15–19 of cycle 1 and again on\n days 1–5 of cycle 2.", "Technique": "IHC, Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells, CD4+ FoxP3+ regulatory T cells\n and CD11b+ myeloid cells", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD4+ T cells; CD8+ T cells; T cells; CD11b / ITGAM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/167", "Drug": "Vorinostat and hydroxychloroquine", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB01611", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Hydroxychloroquine: It has been shown that hydroxychloroquine accumulates in the lysosomes of the malaria parasite, raising the pH of the vacuole.4 This activity interferes with the parasite's ability to proteolyse hemoglobin, preventing the normal growth and replication of the parasite.4 Hydroxychloroquine can also interfere with the action of parasitic heme polymerase, allowing for the accumulation of the toxic product beta-hematin", "KEGG_Drug_ID": "D06320, \n D08050", "Pubchem_ID": "5311, \n 3652", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1", "Single/Combination": "Combination", "PMID": "27463016", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Patient_Sample": "n=22", "Male/Female": "2024-07-13 00:00:00", "Median_age/Range": "61 years (range 44–74)", "Dose": "VOR 400 mg PO and HCQ 600 mg PO daily, in a 3-week cycle.", "Technique": "immunohistochemistry(n=2),qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "T cell activation", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; T-cell activation", "Immune_System-Function_inhibited/numbers_decreased": "regulatory T cells (CD25+FoxP3+), myeloid derived suppressor cells (defined as CD11b+HLA-DRlo) and monocytes (CD14+) PD-1 on CD4+and CD8+ T cells autophagy( lysosomal protease cathepsin D and p62 accumulation)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs); CD4+ T cells; CD8+ T cells; T cells; Monocytes; PD-1 / PDCD1; CD14; CD25 / IL2RA; SQSTM1 / p62; CD11b / ITGAM", "Immune_System_function_unaffected": "CD11b+ myeloid cells, dendritic cells (CD11b+CD11c+) or in CD19+ B cells IFN-γ+ and IL-17+", "Controlled_Terms_Unaffected": "B cells; Dendritic cells; IFN-γ; IL-17; CD19; CD11b / ITGAM; CD11c / ITGAX", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/173", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug_ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "Patient_Sample": "1", "Male/Female": "0/1", "Median_age/Range": "74", "Dose": "Chidamide plus Rituximab for three cycles", "Technique": "PET-CT", "Controlled_Technique": "Positron emission tomography–computed tomography (PET-CT)", "Immune_System-Function_enhanced/numbers_increased": "CR achieved", "Controlled_Terms_Function_enhanced_Number_increased": "Treatment response", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/156", "Drug": "FOLFOX regimen (folinic acid, 5-FU and OXP: pre-neoCT biopsies and post-neoCT surgical tissue samples)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "19", "Male/Female": "2024-05-14 00:00:00", "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ TILs IFNγ tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-infiltrating lymphocytes (TILs); IFN-γ; PD-L1 / CD274", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/133", "Drug": "Cetuximab (chemotherapy with cetuximab)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "28075526-", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Patient_Sample": "n = 13", "Male/Female": "2024-03-10 00:00:00", "Median_age/Range": "64.4 (39–78)", "Dose": null, "Technique": "HE staining", "Controlled_Technique": "Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": "CD3+ CD8+ and CD56+cells-intratumoral filteration", "Controlled_Terms_Function_enhanced_Number_increased": "CD56 / NCAM1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/116", "Drug": "Cisplatin and oral etoposide (mPE)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00515 (APRD00359), DB00773", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation.\n \n Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell.", "KEGG_Drug_ID": "D00275, \n D00125", "Pubchem_ID": "5702198, \n 36462", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],\n [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "27752361", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer - Metastatic Non-Small-Cell Lung Cancer", "Patient_Sample": "12", "Male/Female": "2024-02-10 00:00:00", "Median_age/Range": "69 (range 59–83)", "Dose": "cisplatin (30 mg/sqm days 1-3q21) and oral etoposide (50 mg, days 1-15q21) (mPE doublet)", "Technique": "Flow cytometry,Blood cell counts, serum analysis, multiplex cytokine assay", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay; Blood/serum analysis", "Immune_System-Function_enhanced/numbers_increased": "Tcms,activated MDICs", "Controlled_Terms_Function_enhanced_Number_increased": "Tcms,activated MDICs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD4+, CD3+CD8+ and natural killer cells (CD3-CD16+CD56+;NK) cells", "Controlled_Terms_Unaffected": "NK cells; CD16 / FcγRIIIa; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/103", "Drug": "Bevacizumab (mPEBev): cisplatin + oral etoposide (mPE)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00112\n , DB00515 (APRD00359), DB00773", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.\n Formation of DNA cross-links/alkylation.\n \n Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell.", "KEGG_Drug_ID": "D06409,\n D00275, \n D00125", "Pubchem_ID": "46504473,\n 5702198, \n 36462", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],\n [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "27752361", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Patient_Sample": "n=47", "Male/Female": "37M/10F", "Median_age/Range": "62 (range 33–82)", "Dose": "mPEBev", "Technique": "Flow cytometry and bioplex", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "activated (CD8+CD62L+), central-memory (CD8+C45RA−CCR7+;\n Tcm) and long-term memory (CD8+C45RA−CCR7+CD27+) CTLs; a\n trend to increase regulatory T cells (Treg), activated DCs (CD3−CD19−CD11c+CD14+CD15−),\n expressing either CD83 or CD80, activated MDICs (CD11b+CD14+CD15+) IL10 and G-CSF levels HGF, PECAM-1, Leptin, PDGF-BB, G-CSF and IL8", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); T cells; Dendritic cells; IL-8 / CXCL8; IL-10; G-CSF / CSF3; CD80; CD14; CD19; Central memory T cells; CCR7; PDGF-BB; HGF; PECAM-1; Leptin; CD62L; CD11b / ITGAM; CD11c / ITGAX; CD15", "Immune_System-Function_inhibited/numbers_decreased": "IFNγ (Th1), IL4 (Th2)\n and IL17 (Th17) levels VEGF, angiopoietin-2 and\n follistatin", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; IL-4; IL-17; VEGF; Th1 cells; Th2 cells; Th17 cells; Angiopoietin-2; Follistatin", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/114", "Drug": "Trichostatin A +tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "34", "Male/Female": "26M/8F", "Median_age/Range": "34–82 (Median 64)", "Dose": "10 mg lenalidomide (PO) and 1000 mg Ofatumumab IV", "Technique": "Flow cytometry, Multiplex (Luminex)", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD3+ T cells, CD4+ T cells, CD8+ T cells, Treg, CD16+CD56+NK cells, CD57+CD56+ NK cells CCL2, CCL3, CCL4, IFNa2, IL-12p70 Angiogenic factors bFGF, VEGF", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); NK cells; CD4+ T cells; CD8+ T cells; T cells; IL-12; CCL2 / MCP-1; CCL3 / MIP-1α; CCL4 / MIP-1β; VEGF; CD16 / FcγRIIIa; CD56 / NCAM1; CD57; bFGF", "Immune_System_function_unaffected": "Thrombospondin-1", "Controlled_Terms_Unaffected": "Thrombospondin-1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/40", "Drug": "Bevacizumab ( FOLFIRI,FOLFOX4, XELOX)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00112", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.", "KEGG_Drug_ID": "D06409", "Pubchem_ID": "46504473", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "21358206", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Patient_Sample": "51", "Male/Female": "29/22", "Median_age/Range": "60/31–82", "Dose": "5 mg/kg in combination with 2-week regimens and at the dose of 7.5 mg/kg with 3-week regimens.", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "B and T cell", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/62", "Drug": "DC-KRN7000+lenolidamide", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "23100308", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Asymptomatic Multiple Myeloma (AMM)", "Patient_Sample": "N=6", "Male/Female": "4M/2F", "Median_age/Range": "60-73", "Dose": "LEN:10 mg/d for 1-21 days, DC 10 million on day 8 of ach cycle", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD1d−GalCer+Vα24−Vβ11+ subset of iNKT cells, CD16 expression on CD14+ cells(monocytes) soluble IL2 receptor NKG2D ON NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Monocytes; IL-2; CD14; CD16 / FcγRIIIa; NKG2D / KLRK1; iNKT cells; CD1d", "Immune_System-Function_inhibited/numbers_decreased": "Vα24+Vβ11+ classic iNKT cells", "Controlled_Terms_Function_inhibited_Number_decreased": "iNKT cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/96", "Drug": "Sorafenib and temozolomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398, DB00853", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis. MZ is a DNA alkylating agent known to induce cell cycle arrest at G2/M and to eventually lead to apoptosis. At physiologic pH it is converted to the short-lived active compound, MTIC. MTIC is further hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC) and to methylhydrazine.", "KEGG_Drug_ID": "D08524, \n D06067", "Pubchem_ID": "216239, \n 5394", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,\n CN1N=NC2=C(N=CN2C1=O)C(N)=O", "Single/Combination": "Combination", "PMID": "24197135", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Metastatic Melanoma", "Patient_Sample": "63", "Male/Female": "35/28", "Median_age/Range": "48.5 13.8 [22–75]", "Dose": "temozolomide (Schering Plough; 100–150 mg/m2 daily for 7 days every 2 weeks) and sorafenib (Bayer; 400–800 mg twice daily without interruption)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4(+)NKG2D(+) T cells (IL)-15Rα", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; NKG2D / KLRK1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/87", "Drug": "Lenalidomide+Cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00002", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D04687, D03455", "Pubchem_ID": "216326, 46507042", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "24244687", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer - Kras-Mutant Metastatic Colorectal Cancer", "Patient_Sample": "N=29", "Male/Female": "16M, 13F", "Median_age/Range": null, "Dose": "lenalidomide+Cetuximab", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells, Absolute lymphocytes,Central memory T cytotoxic cells, total memory T helper cells, central memory T helper cells, Naive T cytotoxic cells, naive T helper cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Lymphocytes; Central memory T cells", "Immune_System-Function_inhibited/numbers_decreased": "B cells", "Controlled_Terms_Function_inhibited_Number_decreased": "B cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/75", "Drug": "Gemcitabine plus cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB00515 (APRD00359), DB00441", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation, Inhibition of DNA polymerase", "KEGG_Drug_ID": "D00275,D02368", "Pubchem_ID": "5702198, 60750", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Combination", "PMID": "25659373", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Nonsmall-Cell Lung Cancer (NSCLC)", "Patient_Sample": "40 patients", "Male/Female": "2024-10-30 00:00:00", "Median_age/Range": "20-75", "Dose": "gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4(+)CD25(+)FOXP3(+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD25 / IL2RA", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/47", "Drug": "Cetuximab-based therapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25832655", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "Patient_Sample": "n=22", "Male/Female": "2024-09-13 00:00:00", "Median_age/Range": "60", "Dose": "Cetuximab 250 mg/m2 days weekly (after an initial dose of 400 mg/m2), docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, repeated every 21 days-3 cycles, then radiotherapy to 70 Gy (2 Gy/d) with concurrent cetuximab 250 mg/m2 weekly cisplatin 30 mg/m2, then maintenance cetuximab for 6 months", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CD4+CD25hi Treg", "Controlled_Terms_Negative_Regulation": "Regulatory T cells (Tregs)"}, {"ID": "CANIMM/147", "Drug": "Cisplatin-based NAC", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug_ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": null, "PMID": "31404614", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "Patient_Sample": "39 patients with available pre- and post-chemotherapy matched tumor tissues were identified.", "Male/Female": "2024-10-29 00:00:00", "Median_age/Range": "56.5", "Dose": null, "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression on tumor as well as immune cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/86", "Drug": "Lenalidomide-rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00002", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D04687, D03455", "Pubchem_ID": "216326, 46507042", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "27458141", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal, Head And Neck Squamous Cell Cancers (Hnscc)", "Patient_Sample": "N=22", "Male/Female": "16M/6F", "Median_age/Range": "Median=61, range 44–71", "Dose": "Cetuximab 500 mg/m2 every 2\n weeks (days 1 and 15), Lenalidomide (three dose levels 15, 20, and 25 mg daily for 21 days in 28 day cycle.", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "T regulatory cells, T cells, NK cells, and monocytes IL2, IL12, IFNg,\n TNFa, VEGF, and FGF-basic were", "Controlled_Terms_Unaffected": "NK cells; T cells; Monocytes; IFN-γ; IL-2; IL-12; VEGF", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/67", "Drug": "Exemestane plus Entinostat (EE)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00990, DB11841", "Target/s_or_mechanism_of_action": "Exemestane selectively inhibits aromatase activity in vitro, in a time-dependent and irreversible manner, suggesting the mechanism of action that exemestane covalently binds to aromatase as a pseudo-substrate and inactivates the enzyme. Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338, D00963", "Pubchem_ID": "4261, 60198", "STR_LINK_(SMILES)": "[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C,\n NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "27999738", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "blood samples from 34 patients", "Male/Female": "0/34", "Median_age/Range": null, "Dose": "exemestane 25 mg by mouth once daily plus entinostat 5 mg by mouth once weekly continued until progressive disease or unacceptable toxicity", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD14+HLA-DRhi monocytes as a percentage of CD45+ cells HLA-DR expression on the total CD14+ monocyte", "Controlled_Terms_Function_enhanced_Number_increased": "Monocytes; CD14; HLA-DR", "Immune_System-Function_inhibited/numbers_decreased": "monocytic MDSCs, granulocytic MDSCs CD40 on MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs); Monocytic myeloid-derived suppressor cells (M-MDSCs); Granulocytic myeloid-derived suppressor cells (G-MDSCs)", "Immune_System_function_unaffected": "immune checkpoint receptors PD-1, CTLA-4, and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), on T-cell subsets", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CTLA-4; TIM-3", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/34", "Drug": "Gemcitabine and capecitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441,DB01101", "Target/s_or_mechanism_of_action": "Gemicitabine: Inhibition of DNA polymerase, Capecitabine: FdUMP inhibits DNA synthesis by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate.", "KEGG_Drug_ID": "D02368,D01223", "Pubchem_ID": "########", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "26931369", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic -Advanced Pancreatic Ductal Adenocarcinoma", "Patient_Sample": "38 patients", "Male/Female": "24 /14", "Median_age/Range": "64.0 (44–79)", "Dose": "Gemcitabine was given intravenously at 1000 mg m−2 weekly × 3 every 4 weeks with orally administered capecitabine at 1660 mg m−2 per day (830 mg m−2 twice daily) for 3 weeks followed by 1 week's rest", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "GM-CSF, IL-6 and CRP.", "Controlled_Terms_Unaffected": "IL-6; GM-CSF / CSF2; CRP", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1665", "Drug": "Cisplatin and gemcitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB00515 (APRD00359), DB00441", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation, Inhibition of DNA polymerase", "KEGG_Drug_ID": "D00275,D02368", "Pubchem_ID": "5702198, 60750", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Combination", "PMID": "23451142", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Patient_Sample": "30 patients", "Male/Female": "2024-09-21 00:00:00", "Median_age/Range": "62±11.9", "Dose": "first line chemotherapy with CDDP (mean dose 70 mg/m2) on day 1 plus GEM (GEMZAR®; Eli Lilly and Company, Indianapolis, IN; mean dose 1000 mg/m2) on day 1, 8, and 15 of a 28-day cycle. Treatment was planned for a maximum of six cycles (median 4, range 1–6) unless it was discontinued because of progressive disease, stable disease, unacceptable toxicity, or death.", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/119", "Drug": "Entinostat and high dose IL-2", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28939740", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Patient_Sample": "47 patients", "Male/Female": null, "Median_age/Range": "58 (31–68)", "Dose": "One cycle of treatment (85 days) consisted of 2 courses of high dose IL-2 600,000 units/kg administered intravenously every 8 hrs. on day 1–5 and day 15–19 (± 7 days) (maximum 28 doses) 4, and entinostat orally (1–2 hrs. prior to IL-2 infusion) given once every 2 weeks starting on day-14, administered before IL-2 infusion on day 1, 15, and then continuously", "Technique": "Flow cytometry,Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "tumor infiltrating CD8 cells in patients with either prolonged stable disease (SD)or PR ,activated antigen presenting cells (APC)", "Controlled_Terms_Function_enhanced_Number_increased": "Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Treg infiltration, peripheral Treg( in 5 patients who achieved an objective response as compared to 7 patients who had progressive disease)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/149", "Drug": "Docetaxel, cisplatin and 5-FU (TPF)", "Drug_category": "Others/combination", "Drugbank_ID": "1. DB01248 (APRD00932), 2. DB00515 (APRD00359), 3. DB00544", "Target/s_or_mechanism_of_action": "1. Inhibition of tubulin depolymerization, 2. Formation of DNA cross-links/alkylation, 3. Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "1. D07866, 2. D00275, 3. D00584", "Pubchem_ID": "96024562, 5702198, 3385", "STR_LINK_(SMILES)": "Docetaxel-[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0, Cisplatin-[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], 5-FU-FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "28637493", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Squamous Cell Carcinoma (OSCC).", "Patient_Sample": "103", "Male/Female": null, "Median_age/Range": null, "Dose": "docetaxel 75 mg/m2 intravenously on day 1, followed by cisplatin 75 mg/m2 intravenously on day 1, followed by 5-FU 750 mg/m2/day as a 120-h continuous intravenous infusion on days 1 through 5, every 3 weeks for 2 cycles.", "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Ki-67 and NLRP3 in OSCC tissues", "Controlled_Terms_Negative_Regulation": "Ki-67; NLRP3"}, {"ID": "CANIMM/152", "Drug": "FEC + docetaxel", "Drug_category": "Others/combination", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07867", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "14", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/168", "Drug": "5-fluorouracil (5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "25368252", "Cancer_Type": "Rectal", "Cancer_Type_Description": "Rectal - Locally Advanced Rectal Cancer Patients", "Patient_Sample": "52", "Male/Female": null, "Median_age/Range": "63 years", "Dose": "225 mg/m2/day", "Technique": "immunostaining", "Controlled_Technique": "Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor infiltering lymphocytes-T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/141", "Drug": "BRAFi therapy with CTLA-4 blockade", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "24903021", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "immunohistochemical staining, Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+/FoxP3+Treg ratio within the tumor", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs)", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/177", "Drug": "Docetaxel, cisplatin and 5-FU (TPF)", "Drug_category": "Others/combination", "Drugbank_ID": "1. DB01248 (APRD00932), 2. DB00515 (APRD00359), 3. DB00544", "Target/s_or_mechanism_of_action": "1. Inhibition of tubulin depolymerization, 2. Formation of DNA cross-links/alkylation, 3. Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "1. D07866, 2. D00275, 3. D00584", "Pubchem_ID": "96024562, 5702198, 3385", "STR_LINK_(SMILES)": "Docetaxel-[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0, Cisplatin-[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], 5-FU-FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "28637493", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Squamous Cell Carcinoma (OSCC).", "Patient_Sample": "21", "Male/Female": null, "Median_age/Range": null, "Dose": "docetaxel 75 mg/m2 intravenously on day 1, followed by cisplatin 75 mg/m2 intravenously on day 1, followed by 5-FU 750 mg/m2/day as a 120-h continuous intravenous infusion on days 1 through 5, every 3 weeks for 2 cycles.", "Technique": "real-time qPCR + western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "pro-IL-1β in OSCC tissues  NLRP3, Caspase1 in OSCC tissues", "Controlled_Terms_Negative_Regulation": "IL-1 family; NLRP3; Caspase-1"}, {"ID": "CANIMM/165", "Drug": "Combined BRAF + MEK inhibitor (dabrafenib + trametinib)", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881, DB08912, DB08911", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. \n Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D09996, D10064, D10175", "Pubchem_ID": "42611257, 44462760, 11707110", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "23307859", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "Patients 6-18", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "immunohistochemistry and immunofluorescence, Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "restoration of melanoma antigen expression and CD8+ T cell infiltrate which decreased at time of progression   MART, TYRP-1. TYRP-2, and GP100- Melanoma antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; MART antigen; gp100 antigen; TYRP-1; TYRP-2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/144", "Drug": "Bevacizumab+ atezolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00112, DB11595", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors, Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1", "KEGG_Drug_ID": "D06409, D10773", "Pubchem_ID": "46504473, \n 347911207", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27571927", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Patient_Sample": "10", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Intra-tumoral CD8+ T-cell  intra-tumoral MHC-I + Th1 and T-effector markers, and chemokines, most notably CX3CL1 (fractalkine)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Th1 cells; CX3CL1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/148", "Drug": "Docetaxel", "Drug_category": "Others/combination", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/161", "Drug": "Paclitaxel + carboplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB00958, DB01229", "Target/s_or_mechanism_of_action": "1. Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell. 2.Pacilitaxel-Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "1. D01363, 2. D00491", "Pubchem_ID": "38904, 36314", "STR_LINK_(SMILES)": "carboplatin-[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], pacilitaxel- [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/162", "Drug": "Paclitaxel + cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB00515 (APRD00359),DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation,Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D00275, D00491", "Pubchem_ID": "5702198, 36314", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/163", "Drug": "Paclitaxel + trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00072,DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Paclitaxel: Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D03257, D00491", "Pubchem_ID": "46507516, 36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "1", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/155", "Drug": "FEC + paclitaxel + vinorelbine", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "4", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/145", "Drug": "CEF", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "5", "Male/Female": null, "Median_age/Range": null, "Dose": "yclophsphamide (75 mg/m2 , internal use on day 1-14) -epirubicin (60 mg/m2 , intravenous injection on day 1 and 8) -5-fluorouracil (500 mg/m2 , intravenous injection on day 1 and 8) / every 4 weeks.", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/150", "Drug": "FEC", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "5", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/154", "Drug": "FEC + paclitaxel + trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "5", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/151", "Drug": "FEC + docetaxel", "Drug_category": "Others/combination", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "14", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/153", "Drug": "FEC + docetaxel + trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07868", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C2", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "14", "Male/Female": null, "Median_age/Range": null, "Dose": "5-fluorouracil (500 mg/m2 , intravenous injection on day 1) -epirubicin (60-100 mg/m2 , intravenous injection on day 1) -cyclophosphamide (500 mg/m2 , intravenous injection on day 1) / every 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/143", "Drug": "5-fluorouracil + cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB00515 (APRD00359),DB00544", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation, Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00275, D00584", "Pubchem_ID": "5702198, 3385", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "29138861", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal Squamous Cell Carcinoma (ESCC)", "Patient_Sample": "8", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/108", "Drug": "Dabrafenib + trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "Melanoma biopsies from patients treated at the Melanoma Institute Australia Sydney and the Netherlands Cancer Institute", "Male/Female": null, "Median_age/Range": null, "Dose": "2 mg orally daily", "Technique": "Flow cytometry, immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltrates", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/175", "Drug": "Dabrafenib + trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Patient_Sample": "paired BRAFV600E positive tumor biopsies from patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "qPCR analysis,histology", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": "CD68, M1 marker CD86 and the M2 marker CD163-indicating an accumulation of M1 and M2 polarized macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; CD86; CD68; CD163", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNFα expression  MITF expression", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; MITF"}, {"ID": "CANIMM/39", "Drug": "Bevacizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00112", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.", "KEGG_Drug_ID": "D06409", "Pubchem_ID": "46504473", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "18193223", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "19", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "DC", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": "immature myeloid cells (Lin− HLA-DR−, B)", "Controlled_Terms_Function_inhibited_Number_decreased": "HLA-DR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/41", "Drug": "Bevacizumab plus chemotherapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB00112", "Target/s_or_mechanism_of_action": "Inhibiting the binding of VEGF to its cell surface receptors.", "KEGG_Drug_ID": "D06409", "Pubchem_ID": "46504473", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "23108136", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Patient_Sample": "9", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/46", "Drug": "Cetuximab-based therapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "23444227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Patient_Sample": "(n=17)", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "EGFR-specific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; EGFR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/74", "Drug": "Gemcitabine based regimen", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02373", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "23860726", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Patient_Sample": "32 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "Eight patients received GEM regimens, 10 received GEM ? S1 regimens, and 14 received GEM ? S1 regimens following radiation therapy (30 Gy). S1 is an orally administered drug consisting of a combination of tegafur, 5-chloro-1,4-dihydroxypyridine, and oteracil potassium. The GEM regimen consisted of an intravenous dose of 1,000 mg/m2 GEM on days 1, 8, and 15, repeated every 4 weeks. The GEM ? S1 regimen consisted of an intravenous dose of 1,000 mg/m2 GEM on days 8 and 15, combined with 60 mg/m2 oral S-1 on days 1–14. All patients received two to six courses of chemotherapy", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": "CD4 T cells, CD8 T cells and NK cells (CD3-CD56 cells)", "Controlled_Terms_Unaffected": "NK cells; CD4+ T cells; CD8+ T cells; T cells; CD56 / NCAM1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/65", "Drug": "Docetaxel+cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "1. D07866, 2. D00275", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C3", "Single/Combination": "Combination", "PMID": "24868562", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Nonsmall-Cell Lung Cancer (NSCLC)", "Patient_Sample": "17 NSCLC patients- treated for 4 cycles.", "Male/Female": null, "Median_age/Range": null, "Dose": "cisplatin (75 mg/m2) plus docetaxel (30 mg/m2", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "T reg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/70", "Drug": "Folinic acid, 5-fluorouracil (5FU), and CPT11", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25209187", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "4", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "MDSCs", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells (MDSCs)"}, {"ID": "CANIMM/71", "Drug": "Folinic acid, 5FU, and oxaliplatin", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25209187", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Patient_Sample": "6", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2189", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "28808483", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "12", "Male/Female": "2024-05-07 00:00:00", "Median_age/Range": "38 years, range, 25–54 years", "Dose": "400 mg/day", "Technique": "Flow cytometry.ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+ T cells IL-10, IL-4 and TGF-β FOXP3, GITR and CTLA-4", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4+ T cells; T cells; IL-4; IL-10; TGF-β; CTLA-4; CD25 / IL2RA; GITR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/7", "Drug": "SAHA and cladribine", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB00242", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). \n cladribine is phosphorylated by deoxycytidine kinase to the nucleotidecladribine triphosphate (CdATP; 2-chloro-2′-deoxyadenosine 5′-triphosphate), which accumulates and is incorporated into DNA in cells such as lymphocytes that contain high levels of deoxycytidine kinase and low levels of deoxynucleotidase, resulting in DNA strand breakage and inhibition of DNA synthesis and repair.", "KEGG_Drug_ID": "D06320, \n D01370", "Pubchem_ID": "5311, 20279", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1\n NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1", "Single/Combination": "Combination", "PMID": "25284154", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia  - Chronic Lymphocytic Leukaemia (CLL)", "Patient_Sample": "N=13", "Male/Female": null, "Median_age/Range": null, "Dose": "Acalabrutinib treatment: Each cycle is 4 weeks. Cycle 3 indicates samples obtained after 2 cycles (8 weeks into treatment), and cycle 6 indicates samples obtained after 5 cycles (20 weeks into treatment)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ+, IL-4+, and TNF+ cells CD200 and BTLA as well as IL-10 production by CLL cells, CTLA-4 expression on T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; IFN-γ; IL-4; IL-10; TNF-α / TNF; CTLA-4; BTLA", "Immune_System_function_unaffected": "IL-17–producing cells", "Controlled_Terms_Unaffected": "IL-17", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/45", "Drug": "Cetuximab + motolimod", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "29061643", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Patient_Sample": "(n=5)", "Male/Female": null, "Median_age/Range": null, "Dose": "subcutaneous motolimod injection (2.5 mg/m2) and intravenous cetuximab (initial dose of 400 mg/m2 followed by weekly infusions at 250 mg/m2) administered once weekly starting on Day 1 for a minimum of 3 weeks and a maximum of 4 weeks (i.e., Days 1, 8, 15, and 22) prior to scheduled surgery, which was to be performed within 2 days of the last dose of motolimod received", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "EGFR tetramer+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; EGFR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/48", "Drug": "Cetuximab-based therapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29354119", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Patient_Sample": "50 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "Cetuximab was administered in the dose of 500 mg/m2 in combination with irinotecan in the dose of 180 mg/m^2 in 2-week intervals, or as monotherapy in the same regimen", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CD16+, CD56+, and CD16+CD56+ lymphocytes", "Controlled_Terms_Negative_Regulation": "Lymphocytes; CD16 / FcγRIIIa; CD56 / NCAM1"}, {"ID": "CANIMM/4", "Drug": "Cyclophosphamide + mTOR inhibitor everolimus", "Drug_category": "Others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "30652208", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Patient_Sample": "Forty patients", "Male/Female": null, "Median_age/Range": null, "Dose": "50 mg of CTX once daily and continuously administered, in combination with the standard dose of 10 mg everolimus", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "Treg ,mMDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/13", "Drug": "Carboplatin and a taxane", "Drug_category": "Others/combination", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug_ID": "D01363", "Pubchem_ID": "38904", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Combination", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "21 samples", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CCL2 (MCP-1), CCL7 (MCP-3), and CCL8 (MCP-2)-cancer stem-like cell (CSC) phenotype and contributing to tumor relapse", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; CCL7; CCL8"}, {"ID": "CANIMM/1834", "Drug": "Lenalidomide+melphalan and autologous stem cell transplantation (ASCT)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB01042", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Melphalan attaches alkyl groups to the N-7 position of guanine and N-3 position of adenine, leading to the formation of monoadducts, and DNA fragmenting when repair enzymes attempt to correct the error. It can also cause DNA cross-linking from the N-7 position of one guanine to the N-7 position of another, preventing DNA strands from separating for synthesis or transcription. Finally, melphalan can induce a number of different mutations.", "KEGG_Drug_ID": "D04687, \n D00369", "Pubchem_ID": "216326, \n 460612", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,\n N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O", "Single/Combination": "Combination", "PMID": "24032527", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "N=11", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "NKT cell frequency", "Controlled_Terms_Function_inhibited_Number_decreased": "Natural killer T cells (NKT cells)", "Immune_System_function_unaffected": "CD25", "Controlled_Terms_Unaffected": "CD25 / IL2RA", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1993", "Drug": "Thalidomide+dexamethasone", "Drug_category": "Others/combination", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug_ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Combination", "PMID": "31168767", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "23(Not acheving CR or PR)", "Male/Female": null, "Median_age/Range": null, "Dose": "dexamethasone (40 mg/week in\n fit patients and 20 mg/week in unfit patients) median of 10 months", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1994", "Drug": "Thalidomide+melphalan+prednisone", "Drug_category": "Others/combination", "Drugbank_ID": "DB01041, DB01042, DB00635", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells.\n Melphalan attaches alkyl groups to the N-7 position of guanine and N-3 position of adenine, leading to the formation of monoadducts, and DNA fragmenting when repair enzymes attempt to correct the error. It can also cause DNA cross-linking from the N-7 position of one guanine to the N-7 position of another, preventing DNA strands from separating for synthesis or transcription. Finally, melphalan can induce a number of different mutations.\n Prednisone is first metabolized in the liver to its active form, prednisolone, a glucocorticoid agonist corticosteroid", "KEGG_Drug_ID": "D00754, D00369, D00473", "Pubchem_ID": "5426, 460612, 5865", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,\n N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,\n [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "Single/Combination": "Combination", "PMID": "31168767", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Patient_Sample": "45 (complete remission)", "Male/Female": null, "Median_age/Range": null, "Dose": "MPT regimen (melphalan 16 mg/m2/day for 4 days, prednisone 100 mg/day, 4 days, and thalidomide 100 mg/day continuously) was given every 4 weeks for a median of\n 10 months", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD4+ T cells, CD8+ T cells, NK cells, NKT cells, CD19+ B cells,", "Controlled_Terms_Function_enhanced_Number_increased": "Natural killer T cells (NKT cells); NK cells; CD4+ T cells; CD8+ T cells; T cells; B cells; CD19", "Immune_System-Function_inhibited/numbers_decreased": "iNKT cells,CD4+ CD25+ FoxP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD25 / IL2RA; iNKT cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2216", "Drug": "Oral etoposide (mPE)", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00773", "Target/s_or_mechanism_of_action": "Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell.", "KEGG_Drug_ID": "D00125", "Pubchem_ID": "36462", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "27752361", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Patient_Sample": "n=12", "Male/Female": "10M/2F", "Median_age/Range": "69 (range 59–83)", "Dose": "mPE", "Technique": "Flow cytometry and bioplex", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "activated MDICs (CD11b+CD14+CD15+) IL10 and G-CSF levels, IL8 and IFNγ HGF, PECAM-1, Leptin, PDGF-BB, G-CSF and IL8", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-8 / CXCL8; IL-10; G-CSF / CSF3; CD14; PDGF-BB; HGF; PECAM-1; Leptin; CD11b / ITGAM; CD15", "Immune_System-Function_inhibited/numbers_decreased": "IL8 and IFNγ VEGF, angiopoietin-2 and\n follistatin", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; IL-8 / CXCL8; VEGF; Angiopoietin-2; Follistatin", "Immune_System_function_unaffected": "CD3+CD4+, CD3+CD8+ and natural killer cells (CD3-CD16+\n CD56+;NK) cells, central-memory (CD8+C45RA−CCR7+;\n Tcm)", "Controlled_Terms_Unaffected": "NK cells; CD16 / FcγRIIIa; CD56 / NCAM1; Central memory T cells; CCR7", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2197", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "11595690", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "25 patients", "Male/Female": "0/25", "Median_age/Range": "50.6(30-73)", "Dose": "200 mg/m2 q2w, 4 treatments)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "tumor infiltrating lymphocytes (TILs)", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-infiltrating lymphocytes (TILs); Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2203", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C6", "Single/Combination": "Single Drug", "PMID": "19866475", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Patient_Sample": "31 patients with high-risk localized prostate cancer", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "microarray analysis", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CCL2, CXCL10, IL-1β, IL-6 and IL-8", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-6; IL-8 / CXCL8; CCL2 / MCP-1; CXCL10 / IP-10"}, {"ID": "CANIMM/2232", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "18771959", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "Patient_Sample": "55 samples of 35 patients (stage III and stage IV)", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4+ CD25+ Foxp3+ Tcells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD25 / IL2RA", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2242", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C9", "Single/Combination": "Single Drug", "PMID": "24353914", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Carcinoma", "Patient_Sample": "metastatic breast carcinoma", "Male/Female": null, "Median_age/Range": null, "Dose": "(35 mg/m2)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ Teff:Treg and CD8+ Teff:Treg ratios post-treatment , natural killer (NK) cells", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs)", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25highCD127-FoxP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2243", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C8", "Single/Combination": "Single Drug", "PMID": "24353914", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Patient_Sample": "15 patients with hormone refractory metastatic prostate cancer", "Male/Female": null, "Median_age/Range": null, "Dose": "(35 mg/m2)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ratio of CD4+ effector T cells (Teffs) to Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD4+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25highCD127-FoxP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2269", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C4", "Single/Combination": "Single Drug", "PMID": "12085250", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "Fifteen patients received Docetaxel", "Male/Female": null, "Median_age/Range": null, "Dose": "100 mg m^2", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6, GM-CSF, IFN-γ levels,", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-6; GM-CSF / CSF2", "Immune_System-Function_inhibited/numbers_decreased": "IL-1, TNF, and PGE2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; TNF-α / TNF; PGE2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2202", "Drug": "Neoadjuvant trastuzumab", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31618954", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Patient_Sample": "Eight FFPE tumor samples (N=8)", "Male/Female": null, "Median_age/Range": "Patients were between 36 and 61 years of age", "Dose": "neoadjuvant trastuzumab", "Technique": "IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "All seven tumors were also positive for CD8+ T cells, and six out of seven were positive for CD4+ T cells  only four out of eight tumors were positive for the PD-1 immune checkpoint molecule, which is indicative of an exhausted immune environmen high levels of nuclear NF-κB/p65RelA", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; CD8+ T cells; T cells; PD-1 / PDCD1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2186", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug_ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "28260924", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Patient_Sample": "54", "Male/Female": "26/28", "Median_age/Range": "(18 - 75 )years", "Dose": "(orally, 250 mg/day)", "Technique": "Flow cytometry, immunohistochemistry (IHC), cytokine detection kit", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "natural killer cells interferon-gamma (INF-γ)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "interleukin (IL)-6", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6", "Immune_System_function_unaffected": "IL-2, IL-4, and IL-10", "Controlled_Terms_Unaffected": "IL-2; IL-4; IL-10", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "expression of PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2187", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "30705677", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "30", "Male/Female": null, "Median_age/Range": "50 (23–80)", "Dose": "upto 100 mg dasatinib daily", "Technique": "Flow cytometry,killing assay", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "CD3−CD16brCD56dim NK cells, NKG2D and NKp30 of NK cells(activating receptors), NK cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; NKG2D / KLRK1; NKp30 / NCR3; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": "NKG2A-a inhibitory receptor of NK cell", "Controlled_Terms_Function_inhibited_Number_decreased": "NK cells; NKG2A", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2188", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "22211798", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "18", "Male/Female": null, "Median_age/Range": "63 years (range, 21 – 79)", "Dose": null, "Technique": "Flow cytometry,NK-cell reactivity assay, Th e Bio-Plex ™ Suspension Array system", "Controlled_Technique": "Flow cytometry; Cellular cytotoxicity/function assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "CD3 + CD57 + cells, natural killer (NK)-cell interleukin-8 (IL-8), interferon-γ inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1),(GM-CSF) CD56 + CD57 +", "Controlled_Terms_Function_enhanced_Number_increased": "Monocytes; IFN-γ; IL-8 / CXCL8; GM-CSF / CSF2; CCL2 / MCP-1; CXCL10 / IP-10; CD56 / NCAM1; CD57", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2200", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "27698808", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "14", "Male/Female": "2024-04-13 00:00:00", "Median_age/Range": "58.4 years; age range- 23–74 years", "Dose": null, "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "interstitial lymphocytic aggregates and infiltrates-T and B cells CD3 and CD20 infiltrates", "Controlled_Terms_Function_enhanced_Number_increased": "B cells; CD20 / MS4A1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2201", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31019901", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Patient_Sample": "23", "Male/Female": "2024-03-20 00:00:00", "Median_age/Range": "median age of 64.7 years", "Dose": null, "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression in ICs-mostly macrophages", "Controlled_Terms_Negative_Regulation": "Macrophages; PD-L1 / CD274"}, {"ID": "CANIMM/2204", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "22833259", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Patient_Sample": "22 HCC patients", "Male/Female": null, "Median_age/Range": null, "Dose": "sorafenib (400 mg/day, 8–14 weeks)", "Technique": "Flow cytometry, immunoblotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Tregs   phosphorylation of SMAD2 and SMAD3, pJNK and pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); SMAD2; SMAD3; ERK / MAPK; p-JNK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2208", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "24323358", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Patient_Sample": "18", "Male/Female": "2024-04-14 00:00:00", "Median_age/Range": "58 (43-81)", "Dose": null, "Technique": "Flow cytometry, immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "TAMs and TAMs to become M2-like TAMs and TAMs to become M2-like", "Controlled_Terms_Function_inhibited_Number_decreased": "Tumor-associated macrophages (TAMs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2211", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "21533122", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Patient_Sample": "40", "Male/Female": "25/15", "Median_age/Range": "53 (22–73)", "Dose": "400 mg/daily", "Technique": "Flow cytometry.ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD20+CD5+sIgM+ cells IgM,stromal-derived factor-1 and the B-lymphocyte-activating factor of the tumor necrosis factor family,bone morphogenetic proteins-2 and −7", "Controlled_Terms_Function_enhanced_Number_increased": "B cells; Lymphocytes; TNF-α / TNF; CD20 / MS4A1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2213", "Drug": "Nilotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB04868", "Target/s_or_mechanism_of_action": "Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein.", "KEGG_Drug_ID": "D08953", "Pubchem_ID": "644241", "STR_LINK_(SMILES)": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "28808483", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "8", "Male/Female": "2024-05-03 00:00:00", "Median_age/Range": "mean age, 43 years, range, 28–56 years", "Dose": "300 mg twice daily", "Technique": "Flow cytometry.ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-10 and IL-4 GITR and CTLA-4", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-10; CTLA-4; GITR", "Immune_System_function_unaffected": "TGF-β", "Controlled_Terms_Unaffected": "TGF-β", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2214", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "28808483", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "11", "Male/Female": "2024-06-05 00:00:00", "Median_age/Range": "mean age, 43 years, range, 28–56", "Dose": "100 mg/day", "Technique": "Flow cytometry.ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+ T cells IL-10, IL-4 and TGF-β FOXP3, GITR and CTLA-4", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4+ T cells; T cells; IL-4; IL-10; TGF-β; CTLA-4; CD25 / IL2RA; GITR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2218", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "31428530", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "20", "Male/Female": "2024-09-11 00:00:00", "Median_age/Range": "58[30–81]", "Dose": null, "Technique": "Multiplex Inflammation immunoassay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "CD56+ CD16+ NK cells MCP-1, CX3CL1. TWEAK and TRAIL", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; CCL2 / MCP-1; CD16 / FcγRIIIa; CD56 / NCAM1; CX3CL1; TRAIL; TWEAK", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2219", "Drug": "Nilotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB04868", "Target/s_or_mechanism_of_action": "Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein.", "KEGG_Drug_ID": "D08953", "Pubchem_ID": "644241", "STR_LINK_(SMILES)": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "22211798", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "9", "Male/Female": null, "Median_age/Range": "45 years (range, 21 – 73)", "Dose": null, "Technique": "Flow cytometry,NK-cell reactivity assay, Th e Bio-Plex ™ Suspension Array system", "Controlled_Technique": "Flow cytometry; Cellular cytotoxicity/function assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "interleukin-8 (IL-8), interferon-γ inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Function_enhanced_Number_increased": "Monocytes; IFN-γ; IL-8 / CXCL8; CCL2 / MCP-1; CXCL10 / IP-10", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK-cell", "Controlled_Terms_Negative_Regulation": "NK cells"}, {"ID": "CANIMM/2220", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "22211798", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "36", "Male/Female": null, "Median_age/Range": "58 years (range, 21 – 85)", "Dose": null, "Technique": "Flow cytometry,NK-cell reactivity assay, Th e Bio-Plex ™ Suspension Array system", "Controlled_Technique": "Flow cytometry; Cellular cytotoxicity/function assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "interleukin-8 (IL-8), interferon-γ inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1),(GM-CSF)", "Controlled_Terms_Function_enhanced_Number_increased": "Monocytes; IFN-γ; IL-8 / CXCL8; GM-CSF / CSF2; CCL2 / MCP-1; CXCL10 / IP-10", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2221", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "2406856", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "40", "Male/Female": "18/22", "Median_age/Range": null, "Dose": "400 mg.", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2228", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "20839259", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Patient_Sample": "11 patients", "Male/Female": null, "Median_age/Range": null, "Dose": "sorafenib 400 mg twice daily", "Technique": "Flow cytometry and immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tumour-infiltrating Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2229", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19276286", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Patient_Sample": "23", "Male/Female": null, "Median_age/Range": "57 years (range, 41-80),", "Dose": "(50 mg by mouth daily)", "Technique": "Flow cytometry.ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-g –producing T cells IFNgamma", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "MDSC, CD3(+)CD4(+)CD25(hi)Foxp3(+) Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs); CD25 / IL2RA", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2233", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "19351841", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Patient_Sample": "56", "Male/Female": null, "Median_age/Range": null, "Dose": "400 mg- 800 mg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-gamma production IFN-gamma production", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2239", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "23758044", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "42", "Male/Female": "28/14", "Median_age/Range": null, "Dose": "≥400 mg ⁄ <400 mg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "natural killer (NK) cells- interferon (IFN)-γ(+) CD3(-) CD56(+) cells,effector memory CD8(+) T cells, - IFN-γ(+) CCR7(-) CD45RO(+) CD8(+) cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; IFN-γ; CD56 / NCAM1; Effector memory T cells; CCR7; CD45RO", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2241", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "24297450", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "50", "Male/Female": "37/13", "Median_age/Range": "53.7 (range 16–87)", "Dose": "100 mg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T, NK, CD8+ T, and CD57+CD14- cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD14; CD57", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2244", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "24353914", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Patient_Sample": "10", "Male/Female": null, "Median_age/Range": null, "Dose": "50 mg sunitinib monotherapy daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2245", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "25014230", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "19", "Male/Female": "2024-08-11 00:00:00", "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "(MDSCs),Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2248", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "26103598", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "52", "Male/Female": null, "Median_age/Range": null, "Dose": "(100 mg day(-1) )", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "natural killer (NK) cell or cytotoxic T lymphocyte", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2249", "Drug": "Nilotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB04868", "Target/s_or_mechanism_of_action": "Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein.", "KEGG_Drug_ID": "D08953", "Pubchem_ID": "644241", "STR_LINK_(SMILES)": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "26746653", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "9", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "expansion of BM lymphocytes-CD19+ B cells and CD3negCD16/56+ NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; B cells; Lymphocytes; CD19", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2250", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "26746653", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "25", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "expansion of BM lymphocytes-expansion of BM lymphocytes-CD19+ B cells and CD3negCD16/56+ NK cells + Increased PB lymphocyte,increased CD8+CD57+ and CD8+HLA-DR+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; B cells; Lymphocytes; CD19; CD57; HLA-DR", "Immune_System-Function_inhibited/numbers_decreased": "T regulatory cells", "Controlled_Terms_Function_inhibited_Number_decreased": "T reg", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2251", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "26746653", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "71", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "expansion of BM lymphocytes-CD19+ B cells and CD3negCD16/56+ NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; B cells; Lymphocytes; CD19", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2253", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "27540594", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Patient_Sample": "19 patients", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+CD127+ T effector cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD127", "Immune_System-Function_inhibited/numbers_decreased": "CD4+PD-1+ T cells and CD8+PD-1+ T cells, Foxp3+ Tregs IL-10 and TGF-β1", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD4+ T cells; CD8+ T cells; T cells; IL-10; TGF-β; PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2254", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug_ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "27789775", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Triplenegative Breast Cancer  (mTNBC)", "Patient_Sample": "Thirty‐five mTNBC patients", "Male/Female": null, "Median_age/Range": "50 years (range 31–78)", "Dose": "Treatment consisted of oral dosing of cabozantinib at 60 mg daily over a 21‐day cycle. Patients underwent radiographic restaging at 6 weeks and every 9 weeks thereafter. Patients with complete or partial RECIST responses continued to receive study treatment, whereas those with progressive disease were taken off study. Dose reductions for toxicity occurred if patients experienced grade 3 or 4 neutropenia or thrombocytopenia, or nonhematologic adverse events. From the starting dose of 60 mg daily, doses were reduced as needed to 40 and 20 mg daily", "Technique": "Flow cytometry,enzyme‐linked immunosorbent assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "circulating CD3 + cells and CD3 + CD4‐CD8 + T lymphocytes at days 22 and 64 PlGF, VEGF, and VEGF‐D, Plasma CAIX", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Lymphocytes; VEGF", "Immune_System-Function_inhibited/numbers_decreased": "CD14+ monocytes at days 22 and 64", "Controlled_Terms_Function_inhibited_Number_decreased": "Monocytes; CD14", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Plasma sVEGFRl, sMET, sTIE‐2, or bFGF", "Controlled_Terms_Negative_Regulation": "bFGF"}, {"ID": "CANIMM/2258", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "29218828", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "42", "Male/Female": "26/16", "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocytic subset (M-MDSC)", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs); Monocytic myeloid-derived suppressor cells (M-MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2259", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "29407585", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "52", "Male/Female": null, "Median_age/Range": null, "Dose": "100 mg of dasatinib once daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell differentiation (CD3-CD57+/CD3-CD56+)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; CD56 / NCAM1; CD57", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+CD127 low Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD25 / IL2RA; CD127", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2260", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "30151740", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "22", "Male/Female": "2024-08-14 00:00:00", "Median_age/Range": null, "Dose": "(dose range 70–100 mg/day)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "large granular lymphocytes (LGLs)-CD57+ cytotoxic CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; T cells; Lymphocytes; CD57", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2261", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "30705677", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "21", "Male/Female": null, "Median_age/Range": "51 (28–84)", "Dose": "upto 400 mg daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D and NKp30 of NK cells(activating receptors)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; NKG2D / KLRK1; NKp30 / NCR3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2262", "Drug": "Nilotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB04868", "Target/s_or_mechanism_of_action": "Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein.", "KEGG_Drug_ID": "D08953", "Pubchem_ID": "644241", "STR_LINK_(SMILES)": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "30705677", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Chronic Myeloid Leukemia", "Patient_Sample": "37", "Male/Female": null, "Median_age/Range": "50 (29–80)", "Dose": "upto 600 mg nilotinib daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D and NKp30 of NK cells(activating receptors)", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; NKG2D / KLRK1; NKp30 / NCR3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2264", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31391334", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Patient_Sample": "30 patients", "Male/Female": "2024-04-26 00:00:00", "Median_age/Range": "65(56-84)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+Ki67+ T cells producing IFN-γ IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; IFN-γ; Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "ERK+flt-3+ Tregs and MDSCs p-ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); Myeloid-derived suppressor cells (MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2265", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "31704808", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "93", "Male/Female": "58/35", "Median_age/Range": "60.1 (23–85)", "Dose": "h ≤400 mg/d imatinib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "effector/memory CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "eT reg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Effector regulatory T cells (eTregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2266", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "31824308", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "17", "Male/Female": null, "Median_age/Range": null, "Dose": "first line or second line dasatinib (100 mg QD)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "lymphocytosis - redistribution of naïve and memory populations of all lymphocyte subsets including CD4+ and CD8+ T-cells and B-cells.", "Controlled_Terms_Function_enhanced_Number_increased": "Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2268", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "30588140", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Myeloid Leukemia", "Patient_Sample": "24", "Male/Female": "2024-04-20 00:00:00", "Median_age/Range": "54.5", "Dose": null, "Technique": "ELISA +microscopic examination.", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Microscopy", "Immune_System-Function_enhanced/numbers_increased": "lymphocytosis", "Controlled_Terms_Function_enhanced_Number_increased": "Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": "PDMPs, sVCAM-1, and TGFβ1", "Controlled_Terms_Function_inhibited_Number_decreased": "TGF-β", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2272", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "32099055", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Patient_Sample": "53 patients", "Male/Female": "36 males and 17 females", "Median_age/Range": "71 (range, 21–89) years]", "Dose": "400 mg, twice daily", "Technique": "multiplexed fluorescent bead-based immunoassays with the Milliplex Map Kit", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "sBTLA, sLAG-3, sCTLA-4, sPD-1, sCD80, sCD86 and sPD-L1", "Controlled_Terms_Negative_Regulation": "Soluble B- and T-lymphocyte attenuator (sBTLA); Soluble lymphocyte activation gene 3 (sLAG-3); Soluble cytotoxic T-lymphocyte-associated protein 4 (sCTLA-4); Soluble programmed cell death protein 1 (sPD-1); Soluble CD80 (sCD80); Soluble CD86 (sCD86); Soluble programmed death-ligand 1 (sPD-L1)"}, {"ID": "CANIMM/2275", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20948437", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Primary Renal Cell Carcinoma", "Patient_Sample": "7", "Male/Female": null, "Median_age/Range": null, "Dose": "50 mg daily", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "intratumoral Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2276", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20948437", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Patient_Sample": "28", "Male/Female": "2024-04-24 00:00:00", "Median_age/Range": null, "Dose": "50 mg daily", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD3+CD4+CD25(hi) Foxp3+ regulatory T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD4+ T cells; T cells; CD25 / IL2RA", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/19", "Drug": "Cisplatin + acclerated radiotherapy", "Drug_category": "Platinum compounds", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": "D00275", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": null, "PMID": "21765211", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck - Advanced Squamous Cell Carcinoma Of The Head And Neck", "Patient_Sample": "58 samples with advanced squamous cell carcinoma of the head and neck", "Male/Female": null, "Median_age/Range": null, "Dose": "weekly 40 mg/m2)", "Technique": "immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT 6 MODULATION-STAT6-expressing head and neck cancer displayed enhanced recurrence-free survival upon treatment with cisplatin-based chemoradiation compared with patients with STAT6-negative tumors,", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT6", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2284", "Drug": "Cobimetinib + Atezolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB05239 + DB11595", "Target/s_or_mechanism_of_action": "Cobimetinib inhibits MEK1/MAP2K1 and MEK2/MAP2K2; atezolizumab blocks PD-L1/CD274", "KEGG_Drug_ID": "D10405 + D10773", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O", "Single/Combination": "Combination", "PMID": "35833954", "Cancer_Type": "Bile Duct Carcinoma", "Cancer_Type_Description": "Advanced/metastatic biliary tract cancer", "Patient_Sample": "77 randomized/treated; 38 combination arm; immune analyses: 70 PBMC, 51 plasma overall", "Male/Female": "48 Female / 29 Male", "Median_age/Range": "63 years (44–86)", "Dose": "Cobimetinib 60 mg orally daily, 21 days on/7 days off + atezolizumab 840 mg IV every 2 weeks", "Technique": "Flow cytometry, Luminex assay", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "Combination treatment increased CD4⁺TIM3⁺ T cells;BTLA+CD8+ cells, IL-23, IL-8 and RANTES , tumor analysis also showed enhanced antigen-processing/presentation gene expression and increased CD8/FoxP3 ratio", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; IL-8 / CXCL8; IL-23; TIM-3; BTLA; CD4; CD8; FOXP3; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Decreased CD8⁺VISTA⁺ T cells; decreased plasma PDGF-BB, BDNF and PlGF-1", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; VISTA; CD8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "T cells; TIM-3; CD4", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2285", "Drug": "Cobimetinib + Atezolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB05239 + DB11595", "Target/s_or_mechanism_of_action": "Cobimetinib inhibits MEK1/2/MAPK signaling; atezolizumab blocks PD-L1-mediated immune suppression", "KEGG_Drug_ID": "D10405 + D10732", "Pubchem_ID": "16222096 + 138611", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "34389557", "Cancer_Type": "Bile Duct Carcinoma", "Cancer_Type_Description": "Metastatic biliary tract cancers: intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer", "Patient_Sample": "34", "Male/Female": null, "Median_age/Range": "63 years (44–86)", "Dose": "Atezolizumab 840 mg IV days 1 & 15 + cobimetinib 60 mg orally daily, days 1–21 of each 28-day cycle", "Technique": "Flow cytometry; CD8+ T-cell activation analysis", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD38+ CD8+ and PD-1+TIM3− CD8+ populations remained approximately unchanged", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; TIM-3; CD8; CD38", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2286", "Drug": "Carboplatin + Atezolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB11595", "Target/s_or_mechanism_of_action": "Carboplatin: causes DNA damage. Atezolizumab: blocks PD-L1-mediated immune inhibition, potentially restoring T-cell activity", "KEGG_Drug_ID": null, "Pubchem_ID": "426756", "STR_LINK_(SMILES)": "C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]", "Single/Combination": "Combination", "PMID": "37038006", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Metastatic breast cancer, including ER-positive/HER2-negative and triple-negative disease", "Patient_Sample": "26", "Male/Female": "Female", "Median_age/Range": "Median 60 years; range 45–69 years (study population)", "Dose": "Carboplatin: AUC 1.5 mg·mL⁻¹·min⁻¹ weekly for up to 12 weeks; atezolizumab: 1200 mg IV every 3 weeks, beginning in week 3", "Technique": "Flow cytometry; immunohistochemistry; immune-related gene-expression analysis", "Controlled_Technique": "Immunohistochemistry (IHC); Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "Increased tumor-infiltrating CD8+ T cells; increased circulating PD-1+CTLA-4+CD8+ T cells; increased immune-related gene signatures", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; PD-1 / PDCD1; CTLA-4; CD8", "Immune_System-Function_inhibited/numbers_decreased": "Decreased circulating neutrophils, basophils and eosinophils; decreased neutrophil-to-lymphocyte ratio", "Controlled_Terms_Function_inhibited_Number_decreased": "Lymphocytes; Neutrophils; Basophils; Eosinophils", "Immune_System_function_unaffected": "Total circulating T cells, CD4+ T cells and CD8+ T-cell levels were largely unchanged; stromal tumor-infiltrating lymphocytes were largely unaffected", "Controlled_Terms_Unaffected": "CD4+ T cells; CD8+ T cells; T cells; Tumor-infiltrating lymphocytes (TILs); Lymphocytes; CD4; CD8", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "T cells", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2287", "Drug": "Pembrolizumab + mRNA-2752", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Blocks PD-1 signaling, releasing inhibitory signals on antitumor T cells", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "39821301", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "High-risk ductal carcinoma in situ", "Patient_Sample": "10 patients", "Male/Female": "Female", "Median_age/Range": "Median: 46 years; range: 35–80 years", "Dose": "2–8 mg intratumorally; 2–4 doses every 2–3 weeks. Recommended combination dose: 4 mg", "Technique": "multiplex immunofluorescence", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "higher baseline tumor-infiltrating lymphocytes (TILs) ; programmed cell death ligand 1–positive (PD-L1+) cells", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-infiltrating lymphocytes (TILs); Lymphocytes; PD-L1 / CD274", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2288", "Drug": "Pembrolizumab + capecitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037; DB01101", "Target/s_or_mechanism_of_action": "Pembrolizumab blocks PD-1 signaling; capecitabine is converted to 5-fluorouracil and inhibits thymidylate synthase and DNA/RNA synthesis", "KEGG_Drug_ID": "D10574; D01209", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "35086949", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Metastatic TNBC; first- or second-line treatment", "Patient_Sample": "29 patients, 14 patients in capecitabine arm", "Male/Female": "28 female /1 male", "Median_age/Range": "Mean 63 years", "Dose": "Pembrolizumab 200 mg IV day 1 every 3 weeks; capecitabine 2000 mg orally twice daily days 1–7 every 2 weeks", "Technique": "Flow cytometry; T-cell receptor (TCR) immunosequencing", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Tumor-associated T-cell clones expanded in some patients", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "Peripheral CD3+ T cells decreased over time (average fold change −0.42", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; CD3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2289", "Drug": "Pembrolizumab + paclitaxel", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037; DB01229", "Target/s_or_mechanism_of_action": "Pembrolizumab blocks PD-1 signaling; paclitaxel stabilizes microtubules and inhibits cell division", "KEGG_Drug_ID": "D10574; D01705", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "35086949", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Metastatic TNBC; first- or second-line treatment", "Patient_Sample": "29 patients, 15 patients in paclitaxel arm", "Male/Female": "28 female /1 male", "Median_age/Range": "Mean 56 years", "Dose": "Pembrolizumab 200 mg IV day 1 every 3 weeks; paclitaxel 80 mg/m² IV on days 1, 8 and 15 every 3 weeks; dexamethasone premedication also used", "Technique": "Flow cytometry; T-cell receptor (TCR) immunosequencing", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Tumor-associated T-cell clones expanded in some patients", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "Peripheral CD3+ T cells decreased over time (average fold change −0.56)", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells; CD3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2290", "Drug": "Trastuzumab+ nelipepimut-S (NPS/E75) + GM-CSF", "Drug_category": "Others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Binds HER2/ERBB2 extracellular domain; inhibits HER2 signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC); facilitates dendritic-cell uptake/cross-presentation of HER2 antigen and CD8⁺ T-cell priming", "KEGG_Drug_ID": "D03257", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "32071118", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "High-risk, HER2-low expressing breast cancer", "Patient_Sample": "275 disease-free patients after standard therapy,136 NPS+GM-CSF and 139 control", "Male/Female": "Female", "Median_age/Range": "Vaccine arm median 52.2 years; control 50.5 years", "Dose": "Trastuzumab: 8 mg/kg loading, then 6 mg/kg IV every 3 weeks for 1 year. NPS: 1,000 μg + GM-CSF 250 μg, intradermally", "Technique": "dextramer assay", "Controlled_Technique": "Dextramer assay", "Immune_System-Function_enhanced/numbers_increased": "HER2/E75-specific CD8⁺ CTLs", "Controlled_Terms_Function_enhanced_Number_increased": "CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2291", "Drug": "pembrolizumab + radiotherapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "42420295", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Stage IV oligometastatic ccRCC; RAPPORT phase I/II trial", "Patient_Sample": "30 patients", "Male/Female": "23 male; 7 female", "Median_age/Range": "Median 62 years; range 47–80 years", "Dose": "SABR to all metastatic sites followed by 8 cycles of pembrolizumab (200 mg every 3 weeks)", "Technique": "Cytometry by time-of-flight (CyTOF); NanoString gene-expression profiling; multiplex immunohistochemistry (mIHC), flow cytometry", "Controlled_Technique": "Immunohistochemistry (IHC); Flow cytometry; Mass cytometry (CyTOF); NanoString gene-expression profiling", "Immune_System-Function_enhanced/numbers_increased": "Ki-67+ CD8+ and CD4+ T cells; sustained activated, cytotoxic and memory-like T-cell populations; maintenance and sharing of pre-existing tumour-enriched TCR clones; greater baseline intratumoural cytotoxic T-cell infiltration (PD-1+ CD8+ and PD-1+ CD4+ T cells, and to GzmK+ CD8+ T cells) and closer proximity of CD8+ T cells to tumour cells; NK-cell activation, T cell infiltration (CD8B, CD8A, CD3D, CD3E), pro-inflammatory cytotoxicity (GzmM, GzmA, GzmH, GzmK, IFN-γ, NCR1), adaptive immunity (IL-2RB, IL-4, IRF7, PRAME), T cell co-stimulation and activation (TNFRSF9, TNFRSF14, TNFRSF12A, CD80, FOXP3, KLRK, LCK, SAA1), and inhibitory markers (PDCD1, PD-L1, LAG-3, CD274, TIGIT)", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; CD4+ T cells; IL-4; PD-1 / PDCD1; PD-L1 / CD274; LAG-3; TIGIT; CD4; CD8; CD80; Ki-67; FOXP3; Cytotoxicity / cytolysis; T-cell receptor (TCR)", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2292", "Drug": "Pembrolizumab+stereotactic body radiation therapy (SBRT)", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "36252995", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Stage IV non-small cell lung cancer; adenocarcinoma, squamous cell carcinoma and large-cell neuroendocrine tumors", "Patient_Sample": "27 baseline tumor biopsies; 15 matched baseline/on-treatment biopsies and 3 on-treatment-only biopsies were adequate for analysis", "Male/Female": "16 male / 14 female", "Median_age/Range": "61 years (35–75)", "Dose": "Pembrolizumab 200 mg intravenously every 3 weeks; SBRT 8 Gy × 3 fractions on alternate days to one tumor site", "Technique": "Multiplex immunofluorescence for CD3, CD8, CD20, CD103 and FoxP3; pan-cytokeratin staining; HLA-ABC assessment", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Total lymphocytes increased 2.29-fold at 6 weeks; cytotoxic T cells increased 2.80-fold; CD103+ cytotoxic T cells increased 4.87-fold; helper and other T-cell populations increased", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Regulatory T cells (Tregs); T cells; FOXP3", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2293", "Drug": "pembrolizumab + gemcitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "42126144", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Previously treated advanced NSCLC", "Patient_Sample": "16 patients enrolled; pretreatment tumor tissue available for 14", "Male/Female": null, "Median_age/Range": "Median 64 years; range 53–75 years", "Dose": null, "Technique": "Multiplex immunofluorescence", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Tumor inflammation score based on CD3+ T-cell density and spatial proximity to FOXP3+ Tregs was associated with progression-free survival", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); T cells; CD3; FOXP3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Peripheral-blood Treg frequency, PD-L1 expression", "Controlled_Terms_Unaffected": "Regulatory T cells (Tregs); PD-L1 / CD274", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Regulatory T cells (Tregs); T cells; CD3; FOXP3", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2294", "Drug": "Trametinib+ Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/MAP2K1 and MEK2/MAP2K2 inhibitor", "KEGG_Drug_ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Combination", "PMID": "40486486", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Advanced/stage IV non-small-cell lung cancer", "Patient_Sample": "15", "Male/Female": "6 M / 9 F", "Median_age/Range": "69 y (32–81)", "Dose": "1.5 mg or 2 mg orally, days 1–10/according to dose level; RP2D 2 mg", "Technique": "Quantitative immunofluorescence, flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "TIL representing CD4+, CD8+, and CD20+ cells, ratio of CD8+ T-cells to Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD8+ T cells; Tumor-infiltrating lymphocytes (TILs); CD4; CD8; CD20 / MS4A1", "Immune_System-Function_inhibited/numbers_decreased": "T-regulatory cells and MDSCs decreased with trametinib lead-in", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells (MDSCs)", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2295", "Drug": "Brentuximab vedotin + Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB08870+DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D09587+D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "39786430", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Metastatic squamous or nonsquamous NSCLC without actionable genomic aberrations; primary or secondary refractory disease", "Patient_Sample": "55 patients received at least one dose of the combination (12 primary refractory; 43 secondary refractory)", "Male/Female": "Male 35 / Female: 20", "Median_age/Range": "Median: 67 years; overall study age range: 23–86 years", "Dose": "Brentuximab vedotin 1.8 mg/kg IV + pembrolizumab 200 mg IV every 3 weeks; maximum 35 cycles; drugs administered separately on day 1", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor CD8+ T-cell infiltration, especially in responders, ratio of CD8 to Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD8+ T cells; T cells; CD8", "Immune_System-Function_inhibited/numbers_decreased": "Peripheral-blood regulatory T cells (Tregs)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); T cells", "Immune_System_function_unaffected": "CD30+ CD8+ T cells", "Controlled_Terms_Unaffected": "CD8+ T cells; T cells; CD8", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2296", "Drug": "Pembrolizumab + chemotherapy (individual agents NR)", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Pembrolizumab blocks PD-1 signaling; chemotherapy mechanism depends on the agents used", "KEGG_Drug_ID": null, "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "34866339", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Unresectable or recurrent non-small-cell lung cancer; first-line treatment", "Patient_Sample": "49 patients", "Male/Female": null, "Median_age/Range": "68 years (range 52–81 years)", "Dose": null, "Technique": "survival and tumor response analysis", "Controlled_Technique": "Clinical outcome/response assessment", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-1 inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2297", "Drug": "Citarinostat + Oxaliplatin", "Drug_category": "Others/combination", "Drugbank_ID": "DB15449 + DB00526", "Target/s_or_mechanism_of_action": "HDAC6 inhibition/immunomodulation + platinum-mediated DNA damage", "KEGG_Drug_ID": "D10918 + D01790", "Pubchem_ID": "53340426 + 9887054", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "35223194", "Cancer_Type": "Lung Cancer; Adenocarcinoma", "Cancer_Type_Description": "NSCLC / lung adenocarcinoma", "Patient_Sample": "ex-vivo patient tissue culture", "Male/Female": null, "Median_age/Range": null, "Dose": "Ex-vivo ACY241 + oxaliplatin, each at 10 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Enhanced CD8+ T-cell TNF-α/IFN-γ production", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; TNF-α / TNF; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2298", "Drug": "Sintilimab", "Drug_category": "Others/combination", "Drugbank_ID": "DB15765", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks PD-1-mediated inhibitory signaling/checkpoint activity. P PubMed +1", "KEGG_Drug_ID": "D12119", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "38755119", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Relapsed/refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type", "Patient_Sample": "38 treated patients; baseline peripheral blood and pretreatment FFPE tumor samples were evaluated", "Male/Female": "28 male / 10 female (73.7% / 26.3%) P PubMed Central (PMC)", "Median_age/Range": "43 years (20–72) P PubMed Central (PMC)", "Dose": "200 mg IV every 21 days; fixed dose throughout study.", "Technique": "PD-L1 IHC; peripheral-blood flow cytometry for lymphocyte subsets; Th1/Th2 cytokine assay/FACS; plasma ctDNA/EBV-DNA; capture-based NGS. P PubMed Central (PMC)", "Controlled_Technique": "Flow cytometry; Next-generation sequencing (NGS); Immunohistochemistry (IHC); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2299", "Drug": "Pomalidomide + dexamethasone", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910+DB01234", "Target/s_or_mechanism_of_action": "Pomalidomide binds CRBN and promotes IKZF1/IKZF3 degradation; dexamethasone activates the glucocorticoid receptor and has anti-inflammatory and antimyeloma effects", "KEGG_Drug_ID": "D08976+D00292", "Pubchem_ID": "134780+5743", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N and C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C", "Single/Combination": "Combination", "PMID": "25869284", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Relapsed, lenalidomide-refractory multiple myeloma", "Patient_Sample": "39", "Male/Female": "22 male, 17 female (overall study population)", "Median_age/Range": "Overall median 61 years; range NR", "Dose": "Pomalidomide: continuous 2 mg/day, days 1–28, or intermittent 4 mg/day, days 1–21 of each 28-day cycle; dexamethasone: 40 mg weekly (20 mg if age >70 years)", "Technique": "Multiparameter flow cytometry; gene expression profiling; immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC); Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "T-cell and NK-cell activation; interferon-γ, TNFα, IL2, and IL4 by CD4 and CD8 T cells and TNFα and IFNγ by NK cells; increased expression of cytolysis genes, granzymeB and perforin, by CD8 T cells, as well as NK cells; enhanced CD8+ T-cell activation, CD25hiFOXP3+ regulatory T cells, BTLA+ T cells and Tim-3+ NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Regulatory T cells (Tregs); CD8+ T cells; T cells; IFN-γ; TNF-α / TNF; IL-2; IL-4; TIM-3; BTLA; CD4; CD8; Granzyme B / GZMB; Perforin / PRF1; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": "Dexamethasone blunts pomalidomide-mediated T-cell activation", "Controlled_Terms_Function_inhibited_Number_decreased": "T cells", "Immune_System_function_unaffected": "no change in PD1+ T cells", "Controlled_Terms_Unaffected": "T cells; PD-1 / PDCD1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; T cells; TIM-3; BTLA", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2300", "Drug": "Durvalumab + pomalidomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB11714+DB08910", "Target/s_or_mechanism_of_action": "Durvalumab blocks PD-L1; pomalidomide provides immunomodulatory and immune-stimulatory effects", "KEGG_Drug_ID": "D10808+D08976", "Pubchem_ID": "319075068+134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Combination", "PMID": "34385543", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple myeloma", "Patient_Sample": "7", "Male/Female": null, "Median_age/Range": null, "Dose": "Durvalumab 1500 mg IV on day 1; pomalidomide 4 mg orally daily on days 1–21", "Technique": "Flow cytometry, RNA sequencing, T-cell receptor sequencing, multiplex immunofluorescence and electrochemiluminescence assay", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis; Immunofluorescence assay; Enzyme-linked immunosorbent assay (ELISA); T-cell receptor sequencing", "Immune_System-Function_enhanced/numbers_increased": "150–500% increases in proportions of proliferating CD4+ T cells, CD8+ T cells and NK cells; increased CD4+ ICOS+ helper T cells; inferred increases in CD8+ T cells, increase in genes from dendritic cells, monocytes, and macrophages, in addition to CD8 + T cells and Tregs upregulation of IL1B, CXCL1, CXCL9 and inflammatory genes such as TNF, PD-L1 (CD274), and PD-1 (PDCD1), CXCR3, Tim-3 (HAVCR2), and IL7", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells; CD8+ T cells; Regulatory T cells (Tregs); CD4+ T cells; Dendritic cells; Macrophages; Monocytes; TNF-α / TNF; IL-1 family; IL-7; PD-1 / PDCD1; PD-L1 / CD274; TIM-3; CD4; CD8; CXCL9", "Immune_System-Function_inhibited/numbers_decreased": "Reduced B-cell-related gene signatures, including CD19, CD79B and BLK", "Controlled_Terms_Function_inhibited_Number_decreased": "CD19", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Regulatory T cells (Tregs); CD4; FOXP3", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2301", "Drug": "Durvalumab + pomalidomide + dexamethasone", "Drug_category": "Others/combination", "Drugbank_ID": "DB11714+DB08910+DB01234", "Target/s_or_mechanism_of_action": "Durvalumab blocks PD-L1; pomalidomide provides immunomodulatory and immune-stimulatory effects", "KEGG_Drug_ID": "D10808+D08976+D00292", "Pubchem_ID": "134780+5743", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N and C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C", "Single/Combination": "Combination", "PMID": "34385543", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple myeloma", "Patient_Sample": "73", "Male/Female": "AN", "Median_age/Range": "AN", "Dose": "Durvalumab 1500 mg IV on day 1; pomalidomide 4 mg orally daily on days 1–21; dexamethasone 40 mg/day for patients aged 75 or younger, or 20 mg/day for those older than 75, on days 1, 8, 15 and 22", "Technique": "Flow cytometry, RNA sequencing, T-cell receptor sequencing, multiplex immunofluorescence and electrochemiluminescence assay", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis; Immunofluorescence assay; Enzyme-linked immunosorbent assay (ELISA); T-cell receptor sequencing", "Immune_System-Function_enhanced/numbers_increased": "Increases in proliferating CD4+ T cells, CD8+ T cells and NK cells; increased CD4+ and CD8+ ICOS+ subsets and effector-memory T cells; increase in genes from dendritic cells, monocytes, and macrophages, in addition to CD8 + T cells and Tregs; increased IFN-γ 4-gene signature; upregulated IL1B, CXCL1, CXCL9, TNF, CXCR3, HAVCR2 (TIM-3) and IL7; increased T-cell clonality and clonal expansion", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells; CD8+ T cells; Regulatory T cells (Tregs); CD4+ T cells; Dendritic cells; Macrophages; Monocytes; TNF-α / TNF; IL-1 family; IL-7; TIM-3; CD4; CD8; CXCL9; T-cell clonal expansion", "Immune_System-Function_inhibited/numbers_decreased": "Approximately 50% decreases in absolute naive CD8+ T-cell counts and in naive/central-memory CD4+ T-cell populations; Reduced B-cell-related gene signatures, including CD19, CD79B and BLK", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4+ T cells; CD8+ T cells; T cells; CD4; CD8; CD19", "Immune_System_function_unaffected": "IFN-γ", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Regulatory T cells (Tregs); CD4; FOXP3", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2302", "Drug": "Pomalidomide+Dexamethasone+Daratumumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB01234+DB01234+DB09331", "Target/s_or_mechanism_of_action": "Binds cereblon (CRBN), promoting degradation of IKZF1 and IKZF3; immunomodulatory and antimyeloma effects+Glucocorticoid-receptor agonist; anti-inflammatory, immunosuppressive, and antimyeloma activity+Binds CD38 and mediates tumor-cell killing; depletes CD38-expressing immune-cell populations", "KEGG_Drug_ID": "D08976+D00292+NA", "Pubchem_ID": "134780+5743", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N and C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C", "Single/Combination": "Combination", "PMID": "32928795", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Relapsed/refractory multiple myeloma (RRMM)", "Patient_Sample": "Peripheral blood; 110 patients in immune-biomarker subgroup", "Male/Female": null, "Median_age/Range": null, "Dose": "Once daily, days 1–21 of each 28-day cycle; verify exact protocol", "Technique": "Longitudinal flow cytometry and immune phenotyping", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Combination-associated increases in proliferating and activated T cells, CD8⁺ T cells, effector-memory T cells, ICOS⁺ T cells, and proliferating NK cells, Activated CD4+ and CD8+ T-cell frequencies increased after treatment", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; CD4+ T cells; CD8+ T cells; T cells; CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": "Approximately 80% reduction in total NK cells after initial administration; decreased CD19⁺ B cells and depletion of CD38-expressing T-cell subsets; decreased Lin−CD14+HLA−DR−/CD33+CD11b+ M-MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "B cells; Myeloid-derived suppressor cells (MDSCs); Monocytic myeloid-derived suppressor cells (M-MDSCs); NK cells; T cells; CD14; CD19; CD38", "Immune_System_function_unaffected": "Treg numbers broadly stable; no significant increase in T-cell exhaustion during the first two cycles", "Controlled_Terms_Unaffected": "Regulatory T cells (Tregs); T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Myeloid-derived suppressor cells (MDSCs); Regulatory T cells (Tregs); Monocytic myeloid-derived suppressor cells (M-MDSCs)", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2303", "Drug": "Pembrolizumab + XL888", "Drug_category": "Others/combination", "Drugbank_ID": "DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "41448449", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Advanced metastatic, mismatch repair-proficient PDAC; combination treatment following initial 21-day cycle", "Patient_Sample": "17", "Male/Female": "8 male, 9 female", "Median_age/Range": "median 68 years (range: 55–70)", "Dose": "Pembrolizumab 200 mg IV every 21 days + XL888 90 mg orally twice weekly; combination continued after cycle 1 until progression or toxicity", "Technique": "Multiplex assay (48-plex); CyTOF mass cytometry; liver-biopsy immune profiling; multiplex immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC); Cytokine/multiplex immunoassay; Mass cytometry (CyTOF); Tumor tissue/biopsy assessment", "Immune_System-Function_enhanced/numbers_increased": "monocytic cells (CD14+) and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) (CD14+CD33+CD11b+) , Increase in circulating Th1-associated cytokines/chemokines, including IL-15, IL-1β, IL-12p40, IL-12p70, IL-27, CXCL9, CXCL10 and CCL3; CD8+ T cells (CD3+CD8+CCR7−CD27−) and CD4+ regulatory (CD3+CD4+CD25+CD127−CCR4+) T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; Myeloid-derived suppressor cells (MDSCs); Granulocytic myeloid-derived suppressor cells (G-MDSCs); CD4+ T cells; IL-1 family; IL-15; CD3; CD4; CD8; CD14; CD25 / IL2RA; CCL3 / MIP-1α; CXCL9; CXCL10 / IP-10", "Immune_System-Function_inhibited/numbers_decreased": "CD8+:Treg ratio remained unchanged; no significant overall changes in liver-biopsy immune-cell frequencies; no significant treatment-related changes across most tumor microenvironment measures", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); CD8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2304", "Drug": "Dabrafenib+trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "suppresses MAPK/RAF–MEK–ERK signaling, Inhibits MEK1 and MEK2, suppressing downstream MAPK/ERK signaling", "KEGG_Drug_ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F  and CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Combination", "PMID": "33275172", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Nonresectable metastatic, BRAF V600E-mutant melanoma", "Patient_Sample": "Tumor biopsies from 4 patients, collected before and during therapy", "Male/Female": null, "Median_age/Range": null, "Dose": "150 mg orally twice daily", "Technique": "Multiplex immunofluorescence, T-cell receptor β-chain sequencing", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "increased CD4+ T-cell infiltration in all 4 patients; increased CD8+ T-cell infiltration in 2/4;Induction of TCF7 and T-bet was associated with expansion and persistence of antitumor T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; CD8+ T cells; T cells; CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2305", "Drug": "Domatinostat + pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Domatinostat modulates tumor immune microenvironment and antigen presentation; pembrolizumab blocks PD-1 signaling", "KEGG_Drug_ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Advanced unresectable/metastatic cutaneous melanoma", "Patient_Sample": "6", "Male/Female": null, "Median_age/Range": null, "Dose": "Domatinostat 100 mg once daily + pembrolizumab", "Technique": "Tumor biopsy; RNA-seq/gene-expression analysis", "Controlled_Technique": "Gene expression/sequencing analysis; Tumor tissue/biopsy assessment", "Immune_System-Function_enhanced/numbers_increased": "IFNG/IFN-gamma response increased in several patients; antigen-processing machinery/MHC expression increased; cytolytic activity increased; pembrolizumab-response signature increased", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Antigen presentation; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": "PD-1-mediated inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1 / PDCD1", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2306", "Drug": "Ipilimumab (anti-CTLA-4) + Nivolumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30753825", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "57", "Median_age/Range": "64", "Dose": null, "Technique": "Transcriptomic profiling; immune-cell population analysis", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "Anti-tumor T-cell responses associated with treatment response, Intratumoral densities of CD8 and PD-L1 , peritumoral CD8 and PD-1 , intratumoral and peritumoral FOXP3 densities, CD45RO, EOMES, and TBET densities, Granzyme B. CD8+/CD4+EOMES+CD69+CD45RO+ memory T cell phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; CD8+ T cells; T cells; PD-1 / PDCD1; PD-L1 / CD274; CD4; CD8; FOXP3; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "CTLA-4-mediated inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "CTLA-4", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2307", "Drug": "Ipilimumab (anti-CTLA-4) +Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30753825", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "57", "Median_age/Range": "64", "Dose": null, "Technique": "Transcriptomic profiling; immune-cell population analysis", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "Anti-tumor T-cell responses associated with treatment response, Intratumoral densities of CD8 and PD-L1 , peritumoral CD8 and PD-1 , intratumoral and peritumoral FOXP3 densities, CD45RO, EOMES, and TBET densities, Granzyme B. CD8+/CD4+EOMES+CD69+CD45RO+ memory T cell phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD4+ T cells; CD8+ T cells; T cells; PD-1 / PDCD1; PD-L1 / CD274; CD4; CD8; FOXP3; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "CTLA-4-mediated inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "CTLA-4", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2308", "Drug": "Ipilimumab (anti-CTLA-4) + Nivolumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25539810", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Patients receiving concurrent or sequential anti-CTLA-4 and anti-PD-1 therapy", "Patient_Sample": "12", "Male/Female": null, "Median_age/Range": null, "Dose": null, "Technique": "Flow cytometry; mass cytometry (CyTOF); Affymetrix Human Transcriptome 2.0 microarray; qPCR; Luminex cytokine analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis; Cytokine/multiplex immunoassay; Mass cytometry (CyTOF)", "Immune_System-Function_enhanced/numbers_increased": "plasma soluble IL-2 receptor and CXCL10; increased IL-1α; increased IFN-γ production by tumor-infiltrating T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; IL-2; CXCL10 / IP-10", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2309", "Drug": "Brentuximab vedotin + Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB08870+DB09037", "Target/s_or_mechanism_of_action": "Binds PD-1 (PDCD1/CD279) and blocks its interaction with PD-L1 and PD-L2, releasing inhibitory checkpoint signaling and restoring T-cell effector activity", "KEGG_Drug_ID": "D09587+D10574", "Pubchem_ID": "481101797", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "39786430", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Primary or secondary refractory metastatic cutaneous melanoma after progression on PD-1 inhibitor therapy", "Patient_Sample": "58 patients received at least one dose of the combination (17 primary refractory; 41 secondary refractory)", "Male/Female": "Male: 36 / Female: 22", "Median_age/Range": "Median: 64.5 years; overall study age range: 23–86 years", "Dose": "Brentuximab vedotin 1.8 mg/kg IV + pembrolizumab 200 mg IV every 3 weeks; maximum 35 cycles; drugs administered separately on day 1", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor CD8+ T-cell infiltration, especially in responders, ratio of CD8 to Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells (Tregs); CD8+ T cells; T cells; CD8", "Immune_System-Function_inhibited/numbers_decreased": "Peripheral-blood regulatory T cells (Tregs)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells (Tregs); T cells", "Immune_System_function_unaffected": "CD30+ CD8+ T cells", "Controlled_Terms_Unaffected": "CD8+ T cells; T cells; CD8", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2310", "Drug": "Ipilimumab (anti-CTLA-4) + Nivolumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31636098", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "72", "Median_age/Range": null, "Dose": null, "Technique": "Cytokine analysis", "Controlled_Technique": "Cytokine analysis", "Immune_System-Function_enhanced/numbers_increased": "expression of CXCL9, CXCL10, and CXCL11; increased numbers of intratumoral CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; CD8; CXCL9; CXCL10 / IP-10; CXCL11", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2311", "Drug": "Ipilimumab (anti-CTLA-4) +Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31636098", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "72", "Median_age/Range": null, "Dose": null, "Technique": "Cytokine analysis", "Controlled_Technique": "Cytokine analysis", "Immune_System-Function_enhanced/numbers_increased": "expression of CXCL9, CXCL10, and CXCL11; increased numbers of intratumoral CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; CD8; CXCL9; CXCL10 / IP-10; CXCL11", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2312", "Drug": "Ipilimumab (anti-CTLA-4) + Nivolumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31636098", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "56", "Median_age/Range": null, "Dose": null, "Technique": "Cytokine analysis", "Controlled_Technique": "Cytokine analysis", "Immune_System-Function_enhanced/numbers_increased": "expression of CXCL9, CXCL10, and CXCL11; increased numbers of intratumoral CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; CD8; CXCL9; CXCL10 / IP-10; CXCL11", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2313", "Drug": "Ipilimumab (anti-CTLA-4) +Pembrolizumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06186", "Target/s_or_mechanism_of_action": "Blocks CTLA-4-mediated inhibitory signaling", "KEGG_Drug_ID": "D04603", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31636098", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Metastatic melanoma", "Patient_Sample": "Tumor biopsy specimens", "Male/Female": "56", "Median_age/Range": null, "Dose": null, "Technique": "Cytokine analysis", "Controlled_Technique": "Cytokine analysis", "Immune_System-Function_enhanced/numbers_increased": "expression of CXCL9, CXCL10, and CXCL11; increased numbers of intratumoral CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8+ T cells; T cells; CD8; CXCL9; CXCL10 / IP-10; CXCL11", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}]